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ABSTRACT 
 
DESIGN AND SYNTHESIS OF POLYMERIC NANOPARTICLES FOR DRUG AND 
PROTEIN DELIVERY 
 
MAY 2015 
 
JUDY VENTURA,  
 
B. S., UNIVERSITY OF PUERTO RICO, MAYAGUEZ 
 
Ph. D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Sankaran Thayumanavan 
 
     Nanoparticles are emerging as carriers in biological applications due to advances in 
their preparation, size control, surface modification and encapsulation capabilities.  In 
addition, nanomaterials improve bioavailability by enhancing aqueous solubility of the 
guest molecule and increasing resistance time in the body.  However, the delivery of 
guest molecules is still challenging due to the intrinsic characteristics of the guest 
molecule including large size and propensity to denature or degradation in the case of 
biomolecules and the encapsulation stability of the small guest molecules. 
     Our group recently reported the preparation of self-cross-linked polymeric nanogels 
possessing surface functionalization capabilities.  In this dissertation we employed the 
use of polymeric nanogels to explore and understand their guest encapsulation 
capabilities with both hydrophilic and hydrophobic molecules. We were able to 
encapsulate a protein in the hydrophobic core of the nanogels and recover is enzymatic 
activity upon release.  Moreover the surface of these nanogels can be also decorated with 
surface exposed cysteine containing protein. We also reported a straightforward 
methodology for the preparation of tri-functionalized amine materials with high 
functional density. 
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CHAPTER 1 
 
 INTRODUCTION: NANOPARTICLES AS CARRIERS 
1.1 Introduction 
     Nanotechnology is a field of study focused on the development of materials or devices 
at a very small scale. These materials, often called nanoparticles, are defined as particles 
with a size range from 1 to 100 nanometers in diameter. Nanomaterials have gained much 
attention in the scientific community due to their small size, high surface area available 
per unit volume and their ability to adsorb and carry other compounds.1–4 Nanoparticles 
can be fabricated exhibiting morphological diversity such as spheres, hollow spheres, 
cylinders, and disks among others.5–9 The surface of these materials can often be tailored 
to meet the needs of a specific application. Moreover, their diverse chemical composition 
including polymers, metals, biological, carbon and inorganic materials make them a 
fundamental building block in nanotechnology applications.10–16 
     Advances in the preparation, size control, surface modification and encapsulation 
capabilities of nanoparticles make them an ideal carrier for chemical drugs and 
biomolecules.  For instance, their inherent small size allows nanocarriers in the blood 
stream to extravasate through the leaky tumor vasculature, which when combined with 
impaired lymphatic drainage, contributes to the accumulation and retention of 
nanocarriers in the diseased tissue.17 The delivery of nanoscopic carriers is greatly 
influenced by the enhanced permeability and retention (EPR) effect.  In order to achieve 
targeting through the EPR effect, nanocarriers should exhibit sizes within the range of 10-
100 nm. Some organs, such as the kidneys, are capable of filtering positively charged 
particles and can also remove particles smaller than 10 nm (~70 KDa) through renal 
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clearance.18 Additionally, a majority of particles larger than 100 nm are taken up by the 
liver or subjected to clearance by dendritic cells during circulation.18 Furthermore, the 
surface of nanoparticles can be modified with affinity ligands such as antibodies, 
aptamers and peptides that can recognize specific receptors on the cell surface.19–25 These 
receptors should be overexpressed in the diseased cells but not on normal cells in order to 
increase specificity.  Once the nanoparticles recognize and bind to the target cell, 
internalization of the carriers is achieved by receptor-mediated endocytosis.  During this 
process, the cell engulfs the nanocarriers along with extracellular fluids through plasma 
membrane invagination forming a membrane-bound vesicle or endosome. Nanocarriers 
must escape endocytic organelles and reach the cytosol to release their contents before 
being degraded by acidic pH or hydrolases in the endosomes. Various nanostructures 
such as liposomes,26–28 carbon nanotubes,29,30 iron oxide nanoparticles,31–33 gold 
nanoparticles,34,35 polymeric nanoparticles36–38 and dendrimers39,40 have been tested as 
carriers in delivery systems. In this chapter we will discuss the use of polymeric 
nanoparticles as carriers for delivery of (i) hydrophobic small drug molecules and, (ii) 
hydrophilic biomolecules such as proteins and nucleic acids.  
 
1.2 Nanoparticles for Drug Delivery 
1.2.1 Characteristics of a Drug Delivery Carrier 
     Most of the drugs, especially anticancer drugs, are highly lipophilic, polar and 
unstable in aqueous media undergoing less potent decomposition through hydrolysis. 
Systemic administration of these small drugs can cause deleterious side effects since they 
can diffuse across the cell membranes that are not the target of the drug.  Therefore, 
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researchers have been focusing on the development of polymeric materials that will help 
to improve their solubility and to serve as carriers, in order to protect the drug during 
circulation and release it under specific conditions.  Polymeric drug carriers should (i) be 
capable of encapsulating lipophilic drug molecules within their core, (ii) possess a 
desirable size to achieve targeting through the EPR effect, (iii) stably encapsulate the 
guest molecules to prevent premature release, (iv) release their contents in response to a 
specific stimulus triggered by the target cell environment, (v) have an easily modified 
surface for conjugation of targeting ligands, (vi) exhibit low inherent toxicity and (vii) 
have reproducible synthetic methods. The following sections describe the different 
stimuli that have been employed to prepare stimuli responsive nanoparticles.   
1.2.2 Redox Responsive Polymeric Nanoparticles  
     Nanoscopic redox-responsive nanoparticles are particularly attractive because they 
can be cleaved in the presence of high reducing agent concentrations such as reduced 
Figure 1.1 Cartoon representation of intracellular release of redox-responsive 
nanoparticles. 
	   4	  
glutathione (GSH) and thioredoxin.41–48 GSH is found at micromolar concentrations in 
human plasma and about 10 mM in the cytosol of the cells.49 Interestingly, the 
concentration of GSH in the cytosol of cancer cells is seven times higher than that 
observed in normal cells.49 Therefore, development of delivery systems responsive to the 
disulfide functionality by the act of GSH can facilitate intracellular release of 
encapsulated drug molecules (Figure 1).  
     The disulfide functionality can be located into the backbone or side groups of the 
polymeric carriers and the drug molecule can be encapsulated or covalently attached to 
the polymeric carriers. In addition, the disulfide bond can also be located at the 
connection of two polymer blocks. A commonly employed strategy is the use of 
amphiphilic polymers containing disulfide functionality within their hydrophobic 
backbone for the preparation of self-assembled micelles. In the presence of GSH, the 
micelles will disassemble due to the loss of amphiphilic character resulting in the release 
of the cargo. Zhou et al. prepared a polymer micelle system containing sheddable 
polyethylenimine (PEI) shells that are deshielded upon cleavage of the disulfide bonds 
from the core of the micelles.50 The drug molecule, in this case doxorubicin, is then 
released into the cytoplasm of the cell. Our group has also reported the preparation of 
micellar aggregates from the self-assembly of amphiphilic polymer composed of 
triethylene glycol and an alkyl chain as the hydrophobic part connected to the backbone 
of the polymer by a disulfide bond.49 Other reports employ the use of redox responsive 
crosslinking moieties on the core or the shell of micellar aggregates resulting in rapid 
disassembly of the micelle upon their reduction. Cheng et al. prepared crosslinked core 
micelles from a biodegradable amphiphilic block copolymer, monomethoxy 
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poly(ethylene glycol)-b-poly(Tyr(alkynyl)-OCA).51 The micelles, prepared with a redox-
responsive crosslinker in the core showed responsiveness towards reducing agents 
resulting in their disruption and subsequent release of the cargo. Our group has developed 
a delivery platform that involves the use of self-crosslinked nanogels composed of an 
amphiphilic random copolymer containing oligoethylene glycol and pyridyldisulfide 
(PDS) units as side chain functionalities.52 These nanogels were developed based on the 
collapse and self cross-linking of a limited number of PDS side chain groups.  Upon their 
reduction, guest molecules such as doxorubicin are released intracellularly facilitating the 
internalization of hydrophobic guest molecules.  
1.2.3 pH Responsive Polymeric Nanoparticles  
     Environmental stimuli such as pH gradient have also been employed to trigger 
changes in the properties of polymeric materials. For example, at the organ level, delivery 
systems have been designed to respond to the differences in the pH of the gastrointestinal 
tract.  The stomach lumen for digestion has a pH between 1-3, the duodenum ~5, the 
jejunum ~6 and ileum 6.6 – 7.5.53–55 A commonly employed approach to achieve drug 
release in the gastric tract is the use of acrylic-based polymers.  At low pH these 
polymers retain their collapse state. An increase in the pH results in the swelling of the 
nanoparticle due to the protonation of the carboxylic groups and loss of hydrogen 
bonds.56 At the tissue level, the extracellular environment of solid tumors is more acidic 
(pH 6.5) than that for normal cells (pH 7.4) due to the lactic acid accumulation.57 A 
strategy employed is to utilize these pH differences to induce hydrophobic-hydrophilic 
transitions of the polymer.  This transition culminates with the disruption of the 
nanoparticles due to the loss of hydrophobic-hydrophilic balance. β-amino ester-
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containing polymers are commonly employed since at pH below 6.5 the protonation of 
the amine converts the polymer from hydrophobic to hydrophilic.58,59 Targeting acid 
responsiveness at the cellular level can also be achieved through the pH value of 
compartments, such as early endosome and lysosomes decreasing to values of 5.0 or 
lower.60 Amine-containing polymers such as polyethylenimine, poly(amidoamine) and 
imidazole containing polymers that buffer the pH of intracellular compartments have 
been commonly used to improve endosomal escape.61 Scheme 1.1 illustrates some pH 
labile crosslinkers. 
 
 	  	  
 
1.2.4 Light Responsive Polymeric Nanoparticles  
     Light is another stimulus utilized to induce phase transition in polymers and 
subsequent collapse of the carriers. To achieve light responsiveness, photochromic 
moieties are incorporated into the structure of the polymeric nanoparticles.  These 
molecules or chromophores undergo photo-induced structural changes resulting in an 
increase in the polarity (water solubility) of the block. Cyclization, structural 
isomerization or ring opening are some of the transformations of the moieties upon 
irradiation at a certain wavelength. Azobenzene is a chromophore commonly employed 
due to its rapid trans-to-cis photoisomerization upon irradiation.62,63 This isomerization 
causes an increase in the dipole moment and on the lower critical solution temperature 
(LCST) of the molecule.62,63 Salicylideneaniline is another molecule that undergoes 
N N
H
R''
R'
R
Hydrazone
O
O
O
R'
R
Orthoester
R
N R'
Imine
R O S R''
O
B-Thiopropionate
Scheme 1.1 Example of some pH labile crosslinkers. 
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isomerization from the enol to the trans-keto form upon irradiation with UV light 
(Scheme 1.2).64 Spiropyran and fulgimides are photochromic molecules that undergo 
photoisomerization as well.65 Coumarin and ortho-nitrobenzyl groups are also molecules 
whose structures change.  For example coumarins can crosslink after photochemical 
driven [2 + 2] addition reaction and ortho-nitrobenzyl groups cleave upon light 
irradiation.66  
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
1.2.5 Temperature Responsive Polymeric Nanoparticles  
     Changes in the solubility, conformation and hydrophobic-hydrophilic balance of 
polymers can be achieved by variations in temperature.  For instance, poly(N-isopropyl 
acrylamide) (PNIPAM) below its LCST (32oC) exist as an expanded coil in a swollen 
hydrate.67 Upon heating the polymer shrinks, collapsing into a globular state and 
becoming more hydrophobic.68 Poly(dimethylamino)ethyl methacrylate (PDMA) possess 
N N
trans-azobenzene
N N
cis-azobenzene
OH
N N
H
O
enol form
salicylideneaniline
trans-keto form
salicylideneaniline
UV
UV
Visible
Visible
Scheme 1.2 Isomerization of azobenzene and salicylideneaniline. 
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a LCST between 40-50oC and along with ethylene glycol-based polymers undergo 
hydrophilic-to-hydrophobic phase transitions.69 Another property utilized to prepare 
thermoresponsive materials is the upper critical solution temperature (UCST) that 
represents the temperature at which the components of a mixture are miscible in all 
proportions. Polyoxazolines and polysulfobetaines are common materials showing UCST 
and used as temperature-responsive materials.  
1.3 Nanoparticles for Protein and Nucleic Acid Delivery 
1.3.1 Characteristics of a Biomolecule Carrier 
     Delivery of functional biomolecules such as proteins, siRNA and DNA are gaining 
interest in the scientific community having potential applications in cancer, stem cell 
engineering and genetic disorders.  This is due mostly to the possibility of correcting 
disorders by artificially incorporating a gene and replacing poorly expressed or 
dysfunctional proteins in the cellular machinery. However, the delivery of such 
hydrophilic biomolecules is challenging and limited due to their propensity to denature, 
delicate structure and large size among other reasons. During the preparation and 
development of delivery systems, it is important to keep in mind that carriers should be 
capable of protecting the cargo molecule from enzymatic degradation and efficiently 
translocate it to the cytoplasm or nucleus of the cell, depending on the site of action for 
the cargo molecule. Another important aspect of the carrier is the capability to protect 
and deliver the biomolecule in an active conformation. In the following sections we will 
briefly discuss current approaches employed for the delivery of such biomolecules. 
 
 
	   9	  
1.3.2 Protein Delivery 
     The delivery of proteins can be classified into two categories; non-covalent and 
covalent protein interaction with the nanocarrier.  
1.3.2.1 Non-Covalent Protein-Nanocarrier Interactions 
     Electrostatic assembly or hydrophilic and hydrophobic interactions are non-covalent 
strategies employed to conjugate proteins to polymeric nanocarriers.  Proteins can be 
physically adsorbed by electrostatic forces on the surfaces of polymeric vehicles. For 
instance, Akiyoshi et al. prepared self-assembled cationic nanogels composed of 
cholesteryl group-bearing pullulans.70 These nanogels interacted strongly with two 
proteins of opposite charge, bovine serum albumin (BSA) and β-galactosidase (β-gal). 
This formed monodispersed nanoparticles <50 nm. The nanogel-protein complexes were 
effectively internalized by HeLa cells and the protein was release after cellular uptake.  
Similarly, in another report from Yang et al. the preparation of cationic nanoparticles 
from an amphiphilic copolymer poly{(N-methyldietheneamine sebacate)-co-[(cholesteryl 
oxocarbonylamido ethyl) methyl bis(ethylene) ammonium bromide] sebacate} was 
described.71 These polymers self-assembled and a glycoprotein, lectin A-chain, was 
bound on the surface of the nanoparticles. Size was determined to be about 150 nm by 
dynamic light scattering and the zeta potential was 30 mV.  The cytotoxic effect of 
delivering lectin A-chain was assessed in different cancer cells showing to be effective in 
inducing cell death. A similar approach was developed in our group where nanogels were 
prepared from amphiphilic copolymer containing oligo(ethylene glycol) methacrylate and 
pyridyldisulfide methacrylate.72 These nanogels were functionalized with tri-arginine, a 
cell penetrating peptide providing a cationic character to the surface of the nanocarriers. 
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β-galactosidase was complexed with the nanogels by complementary electrostatic 
interactions and an X-gal activity assay demonstrated that the protein retains its activity 
upon cellular entry. 
1.3.2.2 Covalent Protein-Nanocarrier Interactions 
     Proteins are commonly conjugated to polymeric materials by covalent interactions 
utilizing the surface exposed lysine and/or non-disulfide bonded cysteine residues.  Other 
functional groups can be employed to tether proteins to nanocarriers such as hydroxyl, 
carboxylic acids. Park and co-workers prepared glucose coated polymeric beads using 6-
O-glucosyl methacrylate, styrene and acrylic acid.73 Enhanced green fluorescent protein 
(EGFP) was conjugated to the beads by the acrylic acid monomer and (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide) (EDC) coupling. Fluorescence microscopy showed 
cellular internalization of conjugated EGFP glucose-coated beads into mouse embryonic 
stem (mES) and HeLa cells. Polyethylenimine (PEI) is a polymer widely tested in vitro 
and in vivo applications in different fields. Hughes et al. utilized PEI to conjugate 
phospholipase A2 (PLA2) and to accomplish this they utilized also utilized EDC 
coupling.74 They demonstrated that the conjugate retained PLA2 activity by measuring 
the enzymatic activity of the protein after adding the substrate, dhiheptanoyl thio-PC. The 
consumption of the substrate yielded a yellow color product that was monitored by 
recording the absorption spectra at 405 nm. 
     In 2013, our group reported the covalent conjugation of BSA to polymeric nanogels 
composed of poly(ethylene glycol) methacrylate and pyridyl disulfide (PDS) 
methacrylate.75 Protein-nanogel conjugation was achieved through disulfide linkages.  
BSA contains one non-disulfide bonded cysteine residue but in this case, it was not 
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accessible for conjugation with remaining PDS from the nanogels. Therefore, the protein 
was modified with N-succinimidyl S-acetylthiopropionate and then deprotected to expose 
a thiol group. This modified-protein was then successfully conjugated to the polymeric 
nanogels. Finally, Maynard et al. prepared protein-polymer conjugates by polymerization 
of N-isopropylacrylamide (NIPAAM) and protein macroinitiators.76 The initiators were 
prepared by reacting free cysteines from BSA and T4 lysozyme V131C and then with 
initiators for atom transfer radical polymerization (ATRP). Enzymatic activity 
demonstrated that lysozyme was unaffected by the polymerization conditions and 
polymer conjugation. 
1.3.3 Nucleic Acid Delivery 
     Introduction of nucleic acid such as DNA or RNA to replace a defective gene or to 
manipulate the function/expression of a gene are avenues under investigation with 
implications in genetic diseases. The high molecular weight and persistence length of 
nucleic acid prevent them from crossing the negatively charged lipid bilayer. 
Furthermore, delivery of naked DNA often results in their degradation by proteases and 
rapid clearance culminating in low levels of transfection. Therefore, a delivery system 
capable of crossing the lipid bilayer, escape the endosome and release the nucleic acid 
into the nucleus is essential. There are two vectors commonly employed by researchers; 
viral and non-viral vectors.  Viral vectors are very efficient at introducing foreign nucleic 
acid into the cells machinery however, their use has brought safety concerns about the 
potential to cause severe immune and inflammatory responses. Non-viral methods are 
considered to have low pathogenicity but their transfection efficiency is low. In addition, 
viral vectors are difficult to produce in large scale. Consequently, non-viral methods are 
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still preferred over viral methods representing a powerful tool in gene therapy. In this 
category, two classes of materials have received great attention: cationic lipids and 
cationic polymers. 
1.3.3.1 Cationic Lipids 
     Cationic lipids and liposomes are used as vectors due to their ability to condense 
nucleic acid through complementary opposite charges. Their lipidic nature allows them to 
achieve high transfection efficiencies. Some of the commonly used cationic lipids 
include: 2,3-dioleyloxy-N-[2-spermine carboxamide] ethyl-N,N-dimethyl-1-
propanammonium trifluoroacetate (DOSPA, Lipofectamine), N-[1-(2,3-dimyristyloxy) 
propyl]-N,N-dimethyl-N-(2-hydroxyethyl) ammonium bromide (DMRIE), 
imethyldioctadecylammonium bromide (DDAB), and diotadecyl amidoglyceryl spermine 
(DOGS,Transfectam) among others (Scheme 1.3). In 2011, Lee and colleagues prepared 
cationic lipoplexes from 1,2-Di-O-octadecenyl-3-trimethylammonium propane 
(DOTMA), D-Alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS) 
and cholesterol.77 DOTMA was chosen as a component of the miRNA delivery system 
due to its high transfection efficiency. TPGS was utilized to increase the stability and 
cholesterol was employed as a helper lipid to increase transfection potency. The 
lipoplexes achieved higher transfection efficiencies and 50-fold higher accumulation in 
the lungs when compared to siPORT NeoFX transfection agent. In another report, Fattal 
et al. described the preparation of cationic lipoplexes composed of [2-(2,3-
didodecyloxypropyl)hydroxyethyl]ammonium bromide (DE) and 
dioleoylphosphatidylethanolamine (DOPE) and plasmid pCMV-luc.78 A hyaluronic acid 
(HA) conjugate, HA-DOPE, was prepared and introduced to the DE-DOPE liposomes to 
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target the CD44 receptor present on breast cancer cells. The transfection efficiency of 
lipoplexes containing HA-DOPE increased on cancer cell expressing the CD44 receptor 
when compared to plain polyplexes. Despite the advances in the use of cationic lipids as 
vectors, it is important to keep in mind that different structural aspects of the lipids such 
as head group size and hydrophobic tail length can have a different impact on the 
transfection efficiency, cell internalization and toxicity. Improvements to these delivery 
vectors are constantly under investigation to fit the needs of the gene to be delivered, cell 
type, environment and application. 
1.3.3.2 Cationic Polymers 
     Cationic polymers are gaining interest as nucleic acid vectors due to their ease of 
tuning structural features to achieve targeting capabilities and biocompatibility. In 
addition, facile synthesis, robustness and the stability of the polymer-nucleic acid 
complex make them attractive in gene therapy. Poly-L-lysine (PLL), polyethylenimine 
(PEI) and polyamidoamine dendrimers (PAMAM) are a few examples of commonly and 
extensively studied polymers. As cationic lipids, cationic polymers operate on the same 
fundamental principle; condensing nucleic acid based in charge complementarity. 
However, their transfection efficiency is still lower than that for viral vectors. During the 
last decade, a number of studies have emerged with new designs of polymers for gene 
delivery. For example, Part et al. developed a non-toxic polymeric gene carrier by using a 
biodegradable PLL analogue called poly(α-[4-amino-butyl]-L-glycolic acid) (PAGA) 
(Scheme 1.3).79 This polymer was synthesized by converting the α –amino group of ε–
cbz-L-lysine to a hydroxyl group. They demonstrated that this polymer was able to 
condense plasmid DNA forming nanoparticles of about 326 nm. Moreover, this polymer 
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showed higher transfection efficiencies than PLL and while being non-toxic. 
Polyphosphoester is another polymer that has been utilized as a gene carrier. In 2001, a 
group reported the preparation of biodegradable poly(2-aminoethyl propylene phosphate) 
(PPE-EA) consisting of a phosphoester backbone and aminoethoxy as the side chain.80 
After plasmid DNA complexation, the DNA remained intact following exposure of the 
polyplexes to DNase I. As PAGA, PPE-EA showed higher transfection efficiency than 
PLL in the presence of chloroquine.  
     Neutral polymers can also be employed as gene delivery carriers.  These non-
condensing polymers interact with the nucleic acid by hydrogen bonding and/or van der 
Waals interactions.  Some of these polymers include: polyvinylpyrolidone (PVP), 
polyvinyl alcohol (PVA) and poly(D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol)-
b-poly(D,L-lactic-co-glycolic acid) (PLGA-PEG-PLGA).81 These polymers can facilitate 
cellular uptake protecting the DNA from degradation. 
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Scheme 1.3 Chemical structure of poly(α-[4-amino-
butyl]-L-glycolic acid) (PAGA) and poly(2-aminoethyl 
propylene phosphate) (PPE-EA) used as neutral 
polymers for gene delivery. 
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1.4 Summary and Thesis Overview 
     In this chapter, we discussed the use of polymeric nanoparticles as carriers to 
encapsulate hydrophobic drug molecules and biomolecules such as nucleic acid and 
proteins.  We also described various stimuli employed as triggers to induce the release or 
disassembly of these polymeric nanoparticles.  
     In this dissertation we describe the design and synthesis of polymeric nanogels for 
drug and protein delivery applications. We also describe a methodology to tri-
functionalize polymeric nanoparticles. In the upcoming chapters we discuss (i) the 
silencing of an apoptosis inducing protein through protein-polymer conjugation in 
Chapter 2, (ii) the methodology to multi-functionalized polymeric nanoparticles in 
Chapter 3, (iii) the effect of the hydrophobicity or log P of the guest molecule in the 
encapsulation stability in Chapter 4, (iv) the summary of the thesis and future directions.  
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CHAPTER 2 
STIMULUS-RESPONSIVE POLYMERIC NANOGELS SILENCE AND ALLOW 
SELECTIVE REACTIVATION OF A SUICIDAL PROTEIN  
 
2.1 Introduction  
     Proteins perform vital biological functions, ranging from gene regulation1-2 to 
catalysis of metabolic reactions3-4 and cell signaling5-6 to programmed cell death.7-9 
Proteins are widely used as therapeutics because they often exhibit higher specificity and 
offer more nuanced functions than can be achieved by small synthetic drugs.10-12 
Unfortunately, many of the most biologically important proteins have inherent liabilites 
for manipulation and direct administration, including complications such as tremendous 
flexibility and a metastable “folded” state, large size, propensity to aggregate and 
susceptibility to oxidation or degradation. As a result, the development of protein-
polymer nanoconjugates to stabilize and deliver proteins is gaining tremendous 
interest.13-16 Traditionally, conjugation of proteins to polymeric nanocarriers has been 
quite challenging due to the propensity of proteins to denature during polymer 
conjugation, which often requires using organic solvents and harsh synthesis 
conditions.17-18  
     During the past decade researchers have explored different approaches for conjugating 
proteins to telechelic, branched, star polymers and polymeric supramolecular molecules 
without compromising the activity or integrity of the protein.19-25 A commonly employed 
approach is the covalent conjugation of polymeric reactive side chains with surface 
exposed residues such as lysines and non-disulfide bonded cysteines.26-27 Since proteins 
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may contain more than one reactive residue exposed to the solvent or have poor 
accesibility, there is little control over the conjugation site. To circumvent this, 
researchers have developed genetically modified proteins containing a single cysteine or 
lysine residue available for conjugation,28 but such modifications may have significant 
implications on the stability or function of the protein. Inverse microemulsion methods17-
18, 29-31 are also commonly employed where the protein, monomer, and crosslinker in the 
aqueous phase are dispersed in the organic phase and polymerization is carried out 
around the protein.  Meanwhile, controlled radical polymerization (CRP) methods are 
also gaining popularity and emerging as a powerful tool among researchers where 
proteins are modified with a moiety capable of chain initiation.32-35 Despite this, exposure 
to organic/aqueous phases and separation of unreacted protein or monomer can still be 
challenging, compromising protein integrity. Self-assembly between polymeric 
nanoparticles and proteins is utilized as an alternative method to prevent irreversible 
chemical modification of proteins. Depending on surface charge, proteins can also be 
physically adsorbed by electrostatic forces onto the surface of polymeric vehicles.36-39 
The next challenge in this area is protecting proteins during delivery to prevent 
modification or inactivation. This is particularly applicable in biological milieu, such as 
blood, where proteins can be degraded by proteases, oxidized or subjected to a number of 
other insults. The goal of this work was to develop polymeric nanogels that are capable of 
protecting and delivering large, highly mobile, aggregation prone and enzymatically 
challenging proteins intracellularly. Caspases are one such class of targets.  
     Caspases are cysteine proteases that are known for their exquisite specificity for 
cleaving after particular aspartic acid residues and rapidly inducing apoptotic cell 
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death.40-43 Their ability to trigger apoptosis makes them promising for selective cell 
killing, especially in cancer therapeutics. Among the family of apoptotic caspases, 
caspase-3 is of particular interest due to its major role in cleaving substrates during 
apoptosis as well as its high catalytic rate.44 Caspase-3 also presents five surface-exposed 
cysteine residues in each monomer (Figure 2.8) which can be utilized as handles for 
attachment to polymeric materials using thiol chemistry. Conjugation of caspases to 
polymeric materials is particularly attractive since it harnesses a cell’s own biological 
processes to induce cell death. However, transport of active caspases can be dangerous as 
release in an erroneous location can lead to irreversible proteolytic damage or even 
unwanted apoptotic death. The therapeutic potential of caspases for inducing cell death 
could be harnessed if it were possible to silence caspase activity through polymer 
conjugation and then recover its activity upon response to a precise trigger.  
     Our group recently reported self cross-linked polymeric nanogels and demonstrated 
the capability of these vehicles to stably encapsulate hydrophobic molecules and release 
them in response to a specific stimulus.45-47 However, no such strategy exists for 
hydrophilic molecules such as proteins.  We envisioned developing a self-crosslinking 
based strategy to encapsulate proteins using similar polymers, where the redox responsive 
characteristics of the polymer will be utilized to first silence and later activate the 
encapsulated proteins. In this chapter, we explored whether thiol-disulfide exchange 
reactions would be capable of silencing the enzymatic activity of a caspase, protecting the 
protein from denaturation during synthesis and delivery, and finally enabling intracellular 
delivery of an active caspase with the nanogel vehicles. We report the preparation of 
polymeric nanogels to which caspase-3 was reproducibly conjugated either in the interior 
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or on the nanogel surface through disulfide linkages (Scheme 2.1).  These nanogel-
caspase conjugates were further functionalized with a cell penetrating peptide and the 
enzymatic activity of the protein was evaluated upon dissociation from the nanogels. 
 
2.2 Results and Discussion 
2.2.2 Preparation and characterization of nanogel-caspase conjugates  
     In order to form nanogels appropriate for conjugation and transport of hydrophilic 
cargos, it was essential to carefully design the polymer. The random copolymer nanogel 
precursor was obtained by the reversible addition-fragmentation chain transfer (RAFT) 
polymerization of oligo(ethylene glycol) (OEG) methacrylate and pyridyldisulfide (PDS) 
methacrylate.  The feed ratio of the monomer was 50:50 and experimentally the resulting 
Scheme 2.1.  Covalent conjugation of caspase-3 in the interior or on the surface of 
polymeric redox sensitive nanogels. 
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copolymer was found to contain 48% of the OEG units and 52% of the PDS groups as 
discerned by NMR (Figure 2.9). In aqueous solution, this amphiphilic polymer forms 
micelle-like aggregates; these aggregates were locked using a self-crosslinking process.  
This self-crosslinking process was enabled by intra- and inter-chain disulfide cross-
linking of the PDS groups in the presence of the reducing agent dithiothreitol (DTT).  
The nanogel formation process was monitored by tracing the absorption spectra of 
pyridothione (byproduct of the disulfide crosslinking) at 343 nm (Figure 2.10). Based on 
the pyridothione released, the crosslink density of these nanogels was 18% (Figure 
2.10A).  These nanogels were labeled as ‘NG-empty’, since these do not have any cargo 
molecules encapsulated inside.  We then investigated the possibility of localizing and 
attaching the protein to the nanogel: either encapsulated within the crosslinked nanogel 
structure or decorated on the nanogel surface.  To encapsulate caspase-3 within the 
interior, caspase-3 and the amphiphilic polymer were added simultaneously to aqueous 
media.  As a result, caspase-3 was sequestered in the core of the micellar aggregates 
during the self-assembly process of the polymer. The protein was then “locked-in” the 
assembly by initiating thiol-disulfide exchange reactions between PDS groups with 
addition of DTT, trapping caspase-3 within the core of these nanogels (Scheme 2.1, NG-
Casp-In).  It is likely that the exposed cysteines on the caspase also played a role in the 
efficient encapsulation of the proteins within the nanogel.  To take advantage of the 
surface conjugation capabilities of these polymeric materials, we first prepared the cross-
linked nanogels (NG-empty) and caspase-3 was then covalently attached on its surface 
using the cysteine residues of the protein and unreacted PDS groups (Scheme 2.1, NG-
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Casp-Out).  This effectively decorated the nanogel with caspase-3 attached on the 
outside.  
     Due to their hydrophobic nature, we expected that unreacted PDS groups might 
collapse into the core of the nanogels, but found that we could still achieve surface 
functionalization of these nanogels with reasonable efficiency. We also prepared 
nanogels with cell penetrating capabilities by incorporating a cysteine-containing tri-
arginine peptide48-49 on the surface of these nanogels to generate NG-EmptyRRR, NG-
Casp-InRRR, NG-Casp-OutRRR (Scheme 2.1). Incorporation of the peptide on the surface 
was confirmed by further increase in the pyridothione absorption spectra (Figure 2.10D, 
E and F).  Based on the pyridothione released, we found that the presence or absence of 
caspase had no overall impact in the ability to conjugate a second molecular entity.  Also, 
the crosslinking densities of these nanogels NG-EmptyRRR, NG-Casp-InRRR, NG-Casp-
OutRRR were each found to be 18%. 
     To further characterize these nanogel-protein conjugates, we evaluated their size by 
dynamic light scattering (DLS) and found that the hydrodynamic diameter of free 
caspase-3, NG-Empty and NG-EmptyRRR were 6, 12, and 10 nm respectively (Figure 
2.1). After the conjugation of caspase to the nanogels, there was an increase in the size of 
the conjugates, indicative of protein conjugation (12 nm – 18 nm, Figure 1A and B). At 
pH 7.4, caspase-3 is negatively charged (pI value of 6.09), whereas CRRR is highly 
positively charged due to the arginine residues. These differences led us to evaluate the 
change in the surface charge of these conjugates by zeta potential measurements. After 
conjugation of caspase-3, the surface charge of NG-Casp-In (-19 mV) did not change 
significantly from the value observed in the original NG-Empty (-17 mV, Figure 1C).  In 
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the case of NG-Casp-Out, the zeta potential value obtained shifted towards -7 mV, 
similar to the value observed for free caspase-3 (-8 mV). After surface decoration of 
nanogels with CRRR, we expected that NG-EmptyRRR would show a positive zeta 
potential value since these nanogels do not have caspase-3 conjugated. As expected, the 
surface charge for NG-EmptyRRR was found to be +18 mV. However, with caspase-3 
conjugation, the surface charge became less positive: +4 mV for NG-Casp-InRRR and +9 
mV for NG-Casp-OutRRR (Figure 2.1D). These results, along with the UV-vis absorption 
spectra recorded during the nanogel-caspase conjugates synthesis (Figure 2.10, 2.11), 
suggest that unreacted PDS groups from the nanogels were sterically available to 
covalently react with the surface exposed cysteine residues from caspase-3.  Furthermore, 
despite the presence of a large and bulky biomacromolecule on these polymeric nanogels, 
subsequent surface functionalization by CRRR addition can also be achieved, 
demonstrating the prevalent accessibility and reactivity of the PDS groups. The properties 
of these nanogel-caspase conjugates are summarized in Table 2.1. 
 
 
 
 
 
 
 
 
 
Table 2.1. Summary of the Properties of Nanogels, Caspase-
3 and Nanogel-Caspase Conjugates. 
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     To further assess the protein conjugation to the nanogels, we utilized sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to assess caspase dissociation 
from the nanogels in a reducing environment (Figure 2.2).  When treated with SDS, 
caspase-3 dissociates into the constituent large and small subunits (17 and 12 kDa, 
Figure 2.1 (A) DLS of nanogel-caspase conjugates (B) DLS of nanogel-caspaseRRR 
conjugates (C) ζ-potential of nanogel-caspase conjugates (D) ζ-potential of 
nanogel-caspaseRRR conjugates. 
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respectively), which migrate as two characteristic bands on SDS-PAGE.  We expected 
that caspase-3 covalently conjugated to the inside or outside of nanogels should not be 
observable by SDS-PAGE, because it will remain bound to and migrate (or fail to 
migrate) with the nanogel.  We expected to observe the two caspase-3 bands only after 
treatment of the nanogels with a reducing agent.  As anticipated, we did not observe the 
bands corresponding to caspase-3 in the NG-Casp-In nor NG-Casp-Out samples in the 
absence of reductant (Figure 2.2A). This suggests that caspase-3 is covalently conjugated 
through disulfide bonds and not simply associated through physical adsorption.  Since 
disulfide bonds can be cleaved in the presence of high reducing agent concentrations, we 
hypothesized that we should be able to “unlock” the protein from the assembly by 
exposing the conjugates to DTT. The appearance of the characteristic caspase-3 bands for 
the large and small subunits in both samples, NG-Casp-In and NG-Casp-Out, indicated 
that the protein was released after the reduction of disulfide bonds. This confirmed the 
conjugation of caspase-3 in both the “in” and “out” configurations (Figure 2.2B) and 
demonstrated that these nanogels respond to a specific redox stimulus, namely DTT. We 
estimated the concentration of caspase-3 released from each conjugate by comparing the 
intensity of the bands from nanogel-released caspase to known concentrations loaded into 
neighboring wells.  Both nanogel-caspase conjugates (50 µg) released about 2 µg of 
caspase-3.  Similar results were observed for the nanogels functionalized with the cell-
penetrating peptide, RRR. Under non-reducing conditions, no caspase bands were 
observed for the NG-Casp-InRRR and NG-Casp-OutRRR samples (Figure 2.2C).  When the 
samples were exposed to reducing conditions, we observed the appearance of the bands 
indicative of free caspase-3 released from NG-Casp-InRRR and NG-Casp-OutRRR (Figure 
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2.2D).  The concentration of released caspase-3 from 50 µg NG-Casp-InRRR and NG-
Casp-OutRRR was found to be 1 µg and 0.5 µg, respectively. 
 
 
     A capability that we wish to demonstrate here is that the proteins can be encapsulated 
within the interior of these nanogels or conjugated to the surface of the nanogels by 
simply altering the order of protein conjugation and crosslinking steps. Therefore, to 
determine if the caspase-3 was indeed predictably conjugated in the interior or on the 
surface of the nanogels we performed an enzymatic degradation study. The conjugates 
were exposed to acetonitrile (20% of the total volume) to denature the protein. A protein 
digest was then conducted by the addition of trypsin, a serine protease that hydrolyzes 
peptide bonds strictly after the basic residues arginine and lysine.50 These fragments were 
then analyzed by mass spectrometry (MS).  First, caspase-3 itself was subjected to the 
trypsin treatment conditions and the MS analysis displayed 7 major peaks with m/z values 
	  
Figure 2.2. SDS-PAGE gel validating the nanogel-caspase conjugation through 
reducible disulfide linkages. (A) Nanogel-caspase conjugates under non-reducing 
conditions. (B) Nanogel-caspase conjugates under reducing conditions. (C) Nanogel-
caspaseRRR conjugates under non-reducing conditions. (D) Nanogel-caspaseRRR under 
reducing conditions. 
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of 1018.5238, 1118.5436, 1617.8265, 1764.9102, 1854.8610, 1933.8967 and 1963.9908 
(Figure 3.3A).  The caspase-3 fragments that each of these peaks represent are shown in 
Table 2.2.  
 
 
 
 
 
 
 
 
 
We also analyzed empty nanogels by the same method; as expected, no peaks were 
observed in the mass spectrum (Figure 3.3B).  In the case of the NG-Casp-In, we 
expected that if the caspase-3 was in fact encapsulated within the crosslinked core of the 
assembly, trypsin would not be able to reach the caspase-3 and therefore no signal would 
be observed. As predicted, none of the peaks observed previously for caspase-3 were 
present, suggesting that the protein is “locked-in” and protected from proteolytic 
digestion within the nanogels (Figure 3.3C).  On the other hand, in the case of NG-Casp-
Out, peaks with m/z matching those observed for caspase-3 were detected, demonstrating 
that these caspase molecules are indeed on the outside of the nanogel assemblies and not 
protected from proteolysis like those in the NG-Casp-In state (Figure 3.3D). These results 
	  
Table 2.2. Summary of the Peptide Sequences of Caspase-3 
Detected by Mass Spectrometry 
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demonstrate the versatility of these polymeric materials to covalently bind proteins and 
“cage” the cargo protein within the nanogel, protecting it from enzymatic degradation.    
2.2.2 Encapsulated caspases are active upon release.  
     An attractive aspect of this system is the versatility of these polymeric nanogels to be 
decorated either at the surface with cargo proteins or to “wrap-up” intact active cargo 
proteins, and then release this cargo in response to a redox trigger.  This capability is only 
useful if protein cargos retain enzymatic activity upon release from the nanogels. The 
enzymatic activities of caspase-3 conjugated to the nanogels or released after redox 
stimulus were assessed using a fluorogenic substrate cleavage assay.  Based on 
quantification of caspase-release (Figure 2.2), the activity from the precise quantity of 
Figure 2.3 Mass spectra of (A) caspase-3 (B) NG-Empty (C) NG-Casp-In (D) NG-
Casp-Out. 
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nanogels encapsulating 50 nM caspase-3 was measured under non-reducing conditions 
(Figure 2.4).  Due to the fact that the catalytic cysteine of caspase-3 requires a reducing 
environment to be active, a small amount of DTT (0.5 mM) was added for the “non-
reducing conditions.” This was enough reductant to assess activity of any unbound 
caspase, but not enough to promote disassembly of the nanogels. Under these conditions, 
none of the conjugates exhibited caspase-3 activity, suggesting there is no unbound active 
caspase and the enzyme conjugated to the nanogel is effectively catalytically silenced. 
This silencing could be due to the structural constraints imposed by the nanogels and/or 
the lack of accessibility to the peptide substrate. The fact that no caspase-substrate 
cleavage was observed, even in the NG-Casp-Out nanogels, suggests that even non-
encapsulated caspase have been catalytically silenced. Caspase-3 contains a free and 
highly-reactive cysteine at its surface that is part of its catalytic diad (Cys-285). Due to its 
reactivity, it is likely that this cysteine could be one of the primary amino acids to be 
conjugated to the nanogel.  Thus, in the case of surface incorporated caspase, the 
protein’s observed activity could be silent due to covalent conjugation of the active site 
Cys-285.    
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     The nanogel-caspase conjugates were then incubated in the presence of 100 mM DTT 
to release the caspase-3 cargo. Activity was observed after incubation with 100 mM 
DTT, confirming that the protein is active upon release from the nanogel (Figure 2.4A 
	  	   Figure 2.4 (A) Enzymatic activity of caspase-3 (B) caspase-3 percentage activity recovered 
from nanogel-caspase conjugates was measured under essentially non-reducing (0.5 mM 
DTT) or fully-reducing (100 mM DTT) conditions. At 0.5 mM DTT no disassembly of 
nanogels is observed, whereas at 100 mM DTT full disassembly is observed  (C) enzymatic 
activity of caspase-3 (D) percent activity recovered from nanogel-caspase RRR conjugates. 
This experiment was performed in duplicate on each of two days.	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and C). Released caspase-3 activity reached 17% (Figure 2.4B) upon release from NG-
Casp-In and NG-Casp-Out and 74% for NG-Casp-InRRR and NG-Casp-OutRRR (Figure 
2.4D). An earlier protocol for the construction of caspase-containing nanogels utilized 
lyophilization. Caspase-3 is an obligate heterotetramer, which does not refold 
spontaneously with high yields, so it is not surprising that dramatically lower yields of 
functional protein (0.24-3%) were released from lyophilized nanogels using the older 
protocol (Figure 2.11). Given the 15-74% recovery rates observed currently, it is safe to 
conclude that the conjugation process itself is mild and that the nanogels protect the 
caspase, helping it to avoid denaturation and thus retain enzymatic activity. We were 
surprised to note the higher fraction of recovered caspase-3 activity upon release from the 
triarginine-containing nanogels, NG-Casp-InRRR and NG-Casp-OutRRR (Figure 2.4D) than 
from NG-Casp-In and NG-Casp-Out (Figure 2.4B). This result was puzzling, since both 
these types of nanogels had very similar abilities to induce cellular apoptosis (vide infra). 
A key difference between these nanogels is that the non-functionalized nanogels (NG-
Casp-In, NG-Casp-Out) contain unreacted PDS moieties, while these functional groups 
have been consumed during conjugation of the RRR peptide in the functionalized 
nanogels (NG-Casp-InRRR and NG-Casp-OutRRR). We hypothesized that during release 
from the non-functionalized nanogels that the added DTT is initially increasing the 
percent crosslinking (toward 100%) leaving only a remaining fraction of DTT to liberate 
the caspase from what is then a much more extensively crosslinked nanogel. To test this 
hypothesis, we prepared the non-functionalized nanogel-conjugates as before, with an 
18% crosslinking density and then reacted away the remaining PDS groups using thiol-
terminated PEG (MW 1k) to generate NG-Casp-InPEG and NG-Casp-OutPEG.  Next, the 
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enzymatic activity of capase-3 was assessed after exposing the conjugates to 100 mM 
DTT. SDS-PAGE of the nanogel-caspase PEG-thiol conjugates validated the caspase 
conjugation (Figure 2.5A and B).  Once the non-functionalized nanogel-conjugates were 
protected from additional crosslinking by the addition of PEG groups, it was possible to 
release and recover a high percentage of caspase activity (79% and 86%, Figure 2.5C) 
comparable to those observed for the nanogel-caspaseRRR conjugates. The extent of 
recovered caspase-3 activity is quite remarkable considering the lability of the caspase 
heterotetramer and its dependence on proper formation of the active-site loop bundle for 
activity.  This high yield indicates that these nanogels incorporate their cargo without 
	  
Figure 2.5 SDS-PAGE gel validating the nanogel-caspase conjugation through 
reducible disulfide linkages (A) Nanogel-caspasePEG conjugates under non-reducing 
conditions (B) nanogel-caspasePEG conjugates under reducing conditions (C) percent 
activity recovered from nanogel-caspasePEG conjugates.  
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damaging it, while at the same time remaining robust and responding specifically to a 
redox stimulus.  
2.2.3 Nanogels promote cell internalization  
     The ultimate goal for the use of these nanogel-protein conjugates is deliver enzymes in 
their inactive form and activate them using the innate intracellular environment in 
mammalian cells.  In this case, such caspase delivery is expected to result in cell killing.  
To determine whether caspase-conjugated nanogels are capable of internalization in 
living cells, we monitored the cellular uptake of nanogels upon incubation of the 
conjugates with HeLa cells. Caspase-3 was labeled with fluorescein isothiocyanate 
(FITC) to enable intracellular visualization; the cell nucleus was stained with DRAQ5. 
The fluorescence distribution of FITC and DRAQ5 was observed by confocal 
fluorescence microscopy (Figure 2.6, 2.12).  FITC-caspase-3 was observed for nanogels 
caspase on the surface or inside of nanogels (Figure 2.6A, B), whereas no fluorescence 
was visible in cells treated with FITC-labeled caspase-3 (Figure 2.12), suggesting that the 
protein is not capable of penetrating the cells by itself and requires nanogel conjugation 
for efficient internalization. Cellular uptake of nanogel conjugates is slow. This trend 
mirrors previous reports showing no significant internalization of related nanogels at 
doses of 0.1 mg/mL after 6 hours in HeLa cells.51 To improve uptake, triarginine 
containing peptides were also incorporated into caspase-containing nanogels (NG-Casp-
OutRRR and NG-Casp-InRRR; Scheme 2.1) As predicted, nanogels functionalized with 
RRR displayed higher accumulation of caspase-3 both on the membrane and in the cell 
within this short time frame. This is likely due to the increased local concentration of the 
positively charged RRR and the negatively charged cellular membrane.  Although there 
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is no clear consensus as to the detailed mechanism by which the RRR-targeted 
assemblies are internalized, it is now widely accepted that arginine-rich peptides and their 
cargo are internalized via endocytosis.52-54  
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Figure 2.6 Cellular internalization of the (A) NG-FITC-Casp-In (B) NG-FITC-Casp-Out 
(C) NG-FITC-Casp-InRRR (D) NG-FITC-Casp-OutRRR at 0.5 mg/mL on HeLa cells. Within 
each image set, top left is the FITC channel, which show green color for caspase-3 and top 
right is the DRAQ5 channel, which shows red color for the nucleus. Bottom left is the DIC 
image and bottom right is the overlap of all three. This experiment was performed with 
triplicate visualization on one day. One representative field is shown for each condition. 
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2.2.4 Caspase-nanogel assemblies induce apoptotic cell death  
     Caspase-3 plays a critical role during the apoptotic process, so we anticipated strong 
cell death-inducing potential of these nanogel-caspase conjugates, which release up to 
75% of the caspase-3 cargo in an active form.  The extent of cell death was measured in 
HeLa cells treated with increasing doses of the nanogel conjugates (Figure 2.7).  
Staurosporine, a protein kinase inhibitor known to induce apoptosis55 was used as a 
positive control. After 24 hours, cell viability was measured using Alamar Blue assay. 
Apoptosis is characterized by the marked changes in cell morphology such as cell 
shrinkage and blebbing.56 HeLa cells treated with nanogel caspase conjugates appear to 
be rounded and shrinking similar to as those undergoing apoptosis induced by 
staurosporine (Figure 2.11), suggesting that killing was via an apoptotic route.  
     We anticipated that bare nanogels would be relatively non-toxic and that those 
conjugated to caspase-3 should exhibit higher rates of cell death induction. NG-Empty 
exhibited low cellular toxicity at concentrations up to 1 mg/mL (Figure 2.7A), whereas 
nanogel-caspase conjugates displayed a strong dose response for cell death.  At a 
concentration of 1 mg/mL, the cell viability for both NG-Casp-In and NG-Casp-Out was 
reduced to nearly 20%. To confirm that the cell death observed in the nanogel-caspase 
conjugates was induced by the intracellular release of active caspase-3 aided by the 
nanogels and not by the action of caspase-3 in solution, cells were exposed to free 
caspase-3 utilizing the amount of protein fed during the synthesis of 0.1 mg/mL, 0.5 
mg/mL and 1 mg/mL nanogels (50:1 weight ratio, nanogel:caspase-3).  Since caspase-3 
alone is not expected to effectively penetrate the cell membrane, we anticipated that the 
protein itself should not induce cell death.  As expected, the cell viability observed for 
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caspase-3 was approximately 80% for a concentration up to 1 mg/mL, indicating that the 
vast majority of the cell death observed corresponded to apoptosis induced by the 
intracellular release of active caspase-3 from the polymeric nanogels.  Similar results 
were observed for the case of nanogels decorated with RRR peptide (Figure 2.7B).  At a 
concentration of 1 mg/mL, the cell viability for NG-EmptyRRR was about 80% (Figure 
2.7B); this may be because positively charged RRR peptides directly penetrate the cell 
membrane, causing rupture or damage, thus introducing higher toxicity.57 Similar to the 
nonfunctionalized nanogel caspase conjugates, the RRR nanogels induced cell death in a 
dose responsive manner.  Cell viability for NG-Casp-InRRR and NG-Casp-OutRRR was 
about 30-35% at a concentration up to 1 mg/mL.  Although nanogels lacking any 
targeting peptides (Figures 2.6A, B) show much less cell internalization than the RRR 
nanogels, they are more capable of inducing cell death. At first this result was perplexing, 
with cell internalization studies seemingly uncorrelated with increases in cell death. 
However, upon further investigation we observed that that the RRR-decorated nanogels 
appear to be accumulating on cell membranes, rather than being fully incorporated in the 
cytoplasm where caspases can be released and activated.58 In particular, cationic cell 
penetrating peptides are known to enter cells via endocytosis.52-54 If indeed these 
nanogels are getting trapped in an endosome, they would be unable to release their cargo 
due to the oxidizing environment of this cell compartment.59-60 Even if the nanogel was 
disrupted, the oxidizing conditions and endosomal pH would render the caspase inactive. 
Caspase-3 is optimally active at pH 7.5 with a significant decrease in activity at pH 
values in the endosome (estimated to be from 5 to 6.5)61-62 dropping to just 10% 
remaining activity at pH 6.0.63  Thus, although far fewer NG-Casp exist in cells and NG-
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CaspRRR are more abundant overall, the NG-Casp have greater cell-killing potential, 
presumably due to their more favorable intracellular localization. This points to an 
important finding.  Optimal delivery of caspase will utilize a non-endocytic pathway or 
will require delivery materials capable of endosomal escape. The fact that the nanogels 
(without the cell penetrating peptides) exhibit excellent apoptotic efficiency suggests that 
these nanocarriers are already doing well.  Future generations of caspase-containing 
nanogels that utilize alternate targeting ligands that are capable of cytosolic delivery, 
rather than the triarginine peptides, which are known to accumulate in the endosome, 
should yield even more productive delivery systems, capable of selective cell killing via 
apoptosis at even lower doses. 
 
 
Figure 2.7 Cell viability after 24 hours exposure of HeLa cells with the conjugates (A) 
nanogel-caspase conjugates (B) nanogel-caspaseRRR. * The concentration in the caspase-3 
samples is the feed amount of caspase-3 used when preparing 0.1 mg/mL, 0.5 mg/mL and 
1 mg/mL solutions.  Nanogel:Caspase-3 (50:1). The experiment of figure 7A was 
performed in triplicate on one day. The experiment in figure 7B was performed in 
triplicate on two separate days.  Data from one day is shown. The second day is Figure 
2.13. 
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2.3 Summary 
     In this chapter we report here robust strategies to conjugate active enzymes to 
polymeric nanogels with responsive characteristics, where caspase-3 has been used as the 
active protein cargo.  In this study, we show that: (i) the proteins can be attached to the 
surface of the nanogels or can be encapsulated within the polymeric nanogel. (ii) The 
activity of the protein is completely turned off in both these approaches, a feature that is 
useful when delivering cargos that could have deleterious consequences in off-target 
locations.  (iii) The redox sensitive unlocking event causes the protein to be reactivated, 
allowing recovery of ~80% of the activity.  In addition to showing the versatility of these 
approaches, the fact that these have been demonstrated with a protein that is very prone to 
irreversible unfolding suggests that this approach is broadly applicable to other proteins.  
(iv) The recovery of activity under reducing conditions can be capitalized inside cells, 
where the reducing environment of the cytosol due to high glutathione concentrations is 
targeted as the triggering mechanism. This was discerned by the fact that both 
conjugation approaches provide robust cellular entry, protein release, and apoptotic 
activity.  (v) The nanogel-protein conjugate was able to gain cellular entry, while the 
protein by itself did not enter the cells.  These results, combined with the fact that the 
nanogel by itself is not cytotoxic, suggest that these conjugates are promising protein 
carriers.  (vi) The protein conjugated to the surface of the nanogel is prone to proteolysis, 
while the encapsulated protein is not accessible to proteolytic enzymes.  These results 
suggest that while both approaches are versatile for in vitro protein delivery, the 
encapsulation approach is more promising for future in vivo applications.  (vii) The 
nanogel-protein conjugates, decorated with cell-penetrating peptides, gain cellular entry 
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much more rapidly compared to the unfunctionalized nanogels.  However, the overall 
apoptotic efficiency of the unfunctionalized nanogels is comparable (or even better than) 
to those functionalized with RRR.  These results show that the unfunctionalized nanogels 
end up in the cytosol more effectively, as these are not complicated by electrostatic 
association with cellular membranes.  The fact that the unfunctionalized nanogels are 
slow in cellular uptake, but are more effective in releasing the cargo, bodes well for 
utilizing these vehicles for targeted delivery of other protein cargos.  These efforts are 
currently underway in our laboratories.     
  2.4 Experimental Details 
     Polyethylene glycol monomethyl ether methacrylate (PEGMA) (MW 475), 2,2′-
dithiodipyridine, 2,2′-azobis(2-methylpropionitrile) (AIBN), 4-cyano-4-
(phenylcarbonothioylthio) pentanoic acid (chain transfer agent), D,L-dithiothreitol 
(DTT), and other conventional reagents were obtained from commercial sources and 
were used without further purification, except for AIBN which was purified by 
recrystallization. Pyridyl disulfide ethyl methacrylate (PDSMA) was prepared using the 
previously reported procedure (Macromolecules, 2006, 39, 5595-5597).  1H-NMR spectra 
were recorded on a 400 MHz Bruker NMR spectrometer using the residual proton 
resonance of the solvent as the internal standard.  Chemical shifts are reported in parts per 
million (ppm).  Molecular weight of the polymer was estimated by gel permeation 
chromatography (GPC) in THF using the poly(methyl methacrylate) (PMMA) standard 
with a refractive index detector.  Dynamic light scattering (DLS) measurements were 
performed using a Malvern Nanozetasizer.  UV-Visible absorption spectra were recorded 
on a Varian (Model EL 01125047) spectrophotometer.  Size exclusion chromatography 
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was performed on Amersham Biosciences chromatography system equipped with a GE 
health care life sciences superdex 75 10/300 GL column.  Activity assay was performed 
utilizing Spectramax M5 spectrophotometer. MALDI-MS analyses were performed on a 
Bruker Autoflex III time-of-flight mass spectrometer.  All mass spectra were acquired in 
the reflectron mode, and an average of 200 laser shots at an optimized power (60%) was 
used. Cell imaging was performed using Zeiss 510 META confocal microscope.   
2.4.1, Determination of the number of accessible and reactive cysteine (thiols) on 
caspase-3.  
     A 1.5 mL stock of 10 µM caspase-3 was purified using a NAP25 (GE Healthcare) size 
exclusion column to fully exchange the buffer to 20 mM Tris pH 8.0 and eliminate all 
DTT. The caspase-3 (3.6 µM) was then incubated at room temperature with 50 µM of 
5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) for 30 minutes. The absorbance of this 
reaction was then recorded at 412 nm. The Beer-Lambert law was then used on the 
corrected absorbance with a molar absorptivity for DTNB of 14,150 M-1cm-1 and a path 
length of 1 cm. This yielded 5 DTNB molecules per monomer of caspase, indicating that 
there are 5 accessible and reactive cysteine thiols per monomer of caspase-3. 
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2.4.2 Labeling of Caspase-3 with FITC  
     Fluorescein isothiocyanate isomer I (FITC) was dissolved in a 100 mM sodium 
bicarbonate solution pH 9.0 to a concentration of 1 mg/mL. Caspase-3 (2.65 mg) was 
diluted to 2 mL in 100 mM sodium bicarbonate buffer pH 9.0 with a total of 1.5 mg of 
FITC present. This reaction was protected from light and allowed to stir overnight at 4°C. 
The resulting FITC-labeled caspase-3 was dialyzed in 50 mM Tris pH 7.5, 50 mM NaCl, 
and 2 mM DTT to remove excess FITC. The caspase was then concentrated using a 3k 
Da spin filter and the concentration was measured by UV-vis absorption spectroscopy.   
2.4.3. Synthesis of p(PEGMA-co-PDSMA) (P1)  
     A mixture of PDSMA (536.8 mg, 2.1 mmol), PEGMA (1 g, 2.1 mmol), 4-Cyano-4-
(phenylcarbonothioylthio) pentanoic acid (21 mg, 0.0756 mmol) and AIBN (1.2 mg, 
0.00756 mmol) were dissolved in 3 mL THF in a 10 mL Schlenk flask and degassed by 
performing three freeze-pump-thaw cycles with an argon inflow into the reaction. The 
Figure 2.8 Surface exposed cysteine residues in caspase-3 
	   47	  
reaction vessel was sealed and placed in a pre-heated oil bath at 70°C for 12 hours.  The 
product polymer P1 was then purified by precipitation in cold ether (20 mL) to yield the 
random copolymer.  Yield: 90%. GPC (THF) Mn: 20 K. Đ: 1.5. 1H-NMR (400 MHz, 
CDCl3) δ: 8.45, 7.66, 7.09, 4.20-4.06, 3.80-3.42, 3.01, 2.10-1.65, 1.10-0.80.  The molar 
ratios between the two blocks was determined by the integration of the methoxy proton in 
the polyethylene glycol unit and the aromatic proton in the pyridine and found to be 
48%:52% (PEG:PDS). 
2.4.4. Synthesis of CRRR peptide  
     This peptide was prepared following a previously reported procedure (J. Am. Chem. 
Soc., 2012, 134, 6964-6967) except utilizing a different resin.  Rink Amide AM resin 
(200-400 mesh) was selected as the solid support to prepare the peptide using the solid 
phase synthesis. Peptide was used without further purification.  1H NMR (400 MHz, 
D2O) δ: 4.45-4.52, 4.30-4.41, 4.03-4.11, 3.15-3.26, 2.92-3.01, 1.73-1.96, 1.55-1.96.  MS 
(FAB): exact mass calculated: 590.7.  Found: 590.0 
 
 
 
 
 
 
 
 
 Figure 2.9 NMR spectrum of the CRRR peptide 
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2.4.5 Synthesis of the nanogel-caspase conjugates 
     The nanogels were prepared as follows. NG Empty: The polymer (3 mg) was 
dissolved in 1mL 1X PBS buffer pH 7.4 and the solution was left stirring at 20°C for 15 
minutes.  A measured amount of DTT was added to the micellar aggregates and the 
solution was allowed to crosslink for 1 hour at 20°C.  The resulting nanogels were 
dialyzed at 20°C using a 7000 MWCO membrane.  NG-Casp-In: The polymer (3 mg) 
was dissolved in 1mL 1X PBS buffer pH 7.4 and the solution was left stirring at 20°C for 
15 minutes.  To this micellar aggregate solution, 0.06 mg of caspase-3 was added and the 
mixture was left reacting for 1 hour at 20°C.  A measured amount of DTT was added to 
the solution and was stirred for another hour at 20°C to allow for crosslinking.  The 
resulting nanogels were dialyzed at 20°C using a 7K MWCO membrane and unbound 
caspase-3 was removed by Amicon Ultra Centrifugal Filters MWCO 100,000. NG-Casp-
Out: The polymer (3 mg) was dissolved in 1mL PBS buffer pH 7.4 and the solution was 
left stirring at 20°C for 15 minutes.  A measured amount of DTT was added to the 
micellar aggregates and the solution was allowed to crosslink for 1 hour at 20°C.  Then, 
0.06 mg of caspase-3 was added and the mixture was left reacting for another hour at 
20°C. The resulting nanogels were dialyzed at 20°C using a 7K MWCO membrane and 
unbound caspase-3 was removed by Amicon Ultra Centrifugal Filters MWCO 100,000. 
NG EmptyRRR: To functionalize the surface of the nanogels, the same procedure described 
above for nanogels was followed.  In addition, an excess of the ligand (5 mg), CRRR, 
was added and then stirred for another hour at 20°C.  The resulting nanogels were 
dialyzed at 20°C using a 7K MWCO membrane.  NG-Casp-InRRR: To functionalize the 
surface of the nanogels, the same procedure described above for NG-Casp-In was 
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followed.  In addition, an excess of the ligand (5 mg), CRRR, was added and then stirred 
for another hour at 20°C. The resulting nanogels were dialyzed at 20°C using a 7K 
MWCO membrane and unbound caspase-3 was removed by Amicon Ultra Centrifugal 
Filters MWCO 100,000.  NG-Casp-OutRRR: To functionalize the surface of the nanogels, 
the same procedure described above for NG-Casp-Out was followed.  In addition, an 
excess of the ligand (5 mg), CRRR, was added and then stirred for another hour at 20°C. 
The resulting nanogels were dialyzed at 20°C using a 7K MWCO membrane and 
unbound caspase-3 was removed by Amicon Ultra Centrifugal Filters MWCO 100,000. 
2.4.6 Crosslinking density, caspase conjugation and peptide functionalization  
     The crosslinking density was determined following the reported procedure (J. Am. 
Chem. Soc., 2012, 134, 6964-6967) by calculating the amount of the byproduct, 
pyridothione, and its known molar extinction coefficient (8.08 x 103 M-1 cm-1 at 343 nm) 
(Bioconjugate Chem. 2006, 17, 1376-1384).  The functionalization of the nanogels with 
CRRR peptide was evaluated by the further formation of pyridothione (increase in the 
absorption spectra at 343 nm). 
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Figure 2.10 Absorption spectra of nanogel-caspase conjugates synthesis. A) NG Empty 
(0.1 mg/mL) B) NG-FITC-Casp-In (0.1 mg/mL) C) NG-FITC-Casp-Out (0.1 mg/mL) D) 
NG EmptyRRR (0.05 mg/mL) E) NG-FITC-Casp-InRRR (0.05 mg/mL) F) NG-FITC-Casp-
OutRRR (0.05 mg/mL) 
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2.4.7 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
studies  
     Samples of NG-Empty (50 µg), NG-Casp-In (50 µg), NG-Casp-Out (50 µg), NG-
EmptyRRR (50 µg), NG-Casp-InRRR (50 µg) and NG-Casp-OutRRR (50 µg) were run on a 
16% acrylamide gel under non-reducing conditions (no DTT present).  Identical samples 
were then treated with 100 mM DTT and allowed to sit at 25°C for one hour before SDS-
PAGE.  Using a standard curve of known caspase concentrations the caspase released 
from the nanogels was then quantified using the Bio-Rad Image LabTM software.  This 
yielded the precise amount of caspase released per 50 µg of nanogel.  
2.4.8 Enzymatic degradation experiment   
     Sample solutions of nanogels and nanogel-caspase conjugates (1 mg/mL) with a final 
volume of 0.050 mL were prepared.  The concentration of caspase-3 in the conjugate 
solutions was estimated to be 14 µM based on the feed amount during its synthesis 
(caspase-3 molecular weight = 28,500).  The protein was denatured by adding acetonitrile 
(20% of the total volume) and the solutions were left at room temperature for 10 minutes.  
The digestion of caspase-3 was performed by adding trypsin from porcine pancreas, 4:1 
ratio (caspase-3:trypsin), and incubated for 20 hours at room temperature.  Nanogels 
solution was exposed to the same amounts and conditions as those for nanogel-caspase 
conjugates.    
     The matrix solution was prepared by mixing 22.5 mg of α-cyano-hydroxycinnamic 
acid in 350 µL tetrahydrofuran, 150 µL water and 6 µL of trifluoroacetic acid.  10 µL of 
each of the sample solutions and 10 µL of the matrix solution were mixed and spotted on 
a MALDI target. 
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2.4.9. Activity Assay  
     For measurement of caspase-3 activity, milligrams of nanogel used was varied in 
order to release 50 nM caspase-3 in each experiment.  These nanogel-caspase conjugates 
were incubated in 100 mM DTT for 1 hour in order to fully release the cargo caspase-3. 
Identical samples were subject to 0.5 mM DTT treatment in an identical fashion in order 
to assay for any free, or unbound, caspase-3. The caspase-3 activity was then assayed 
over a 7 minute time course in caspase-3 activity assay buffer containing 20 mM HEPES 
pH 7.5, 150 mM NaCl, 5 mM CaCl2, and 10% PEG 400.  In this experiment, caspase-3 
hydrolyzes the peptide substrate, N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin, 
resulting in the release of the 7-amino-4-methylcoumarin (AMC) moiety as a fluorophore 
that can be quantified over time. The fluorogenic substrate N-acetyl-Asp-Glu-Val-Asp-
AMC, Enzo Lifesciences (Ac-DEVD-AMC), Ex 365/Em495, was added to a final 
concentration of 100 µM to initiate the reaction. These 100 µL assays were performed in 
duplicate in a 96-well microplate at 37°C using a spectramax M5 spectrophotometer. 
 
 
 
 
 
 
 
 
 
 
Figure 2.11 Caspase-3 activity recovered after an 
early protocol for the construction of caspase-
containing nanogels involving lyophilization. 50 nM 
caspase-3 control and 50 nM released from  nanogels. 
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2.4.10. Cell Internalization Studies   
     Cell internalization studies were performed using Zeiss 510 META confocal laser 
scanning microscopy.  HeLa cells were cultured in T75 cell culture flask containing 
Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) with 10% fetal 
bovine serum (FBS) supplement.  The cells were seeded at 100,000 cells/mL in cover 
slip-bottomed Petri dishes and allowed to grow for 1 day at 37°C in a 5% CO2 incubator.  
The cells in 1 mL of culture medium were treated with nanogels and nanogel-FITC-
caspase conjugates (0.5 mg/mL) and were incubated for 4 hours at 37°C before 
monitoring the cells by confocal microscopy.  The nucleus of the cells was stained by the 
addition of DRAQ5 (5 µM). All images were taken using 63x oil immersion objectives 
(excitation at 488 nm for FITC and 543 nm for DRAQ-5).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12 No cellular internalization after 
incubating the cells for 4 hours with FITC-
caspase-3. Within each image set, top left is the 
FITC channel, which show green color for 
caspase-3 and top right is the DRAQ5 channel, 
which shows red color for the nucleus.  Bottom 
left is the DIC image and bottom right is the 
overlap of all three. 
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2.4.11. Apoptosis Studies  
     HeLa cells were cultured in T75 cell culture flasks using DMEM/F12 with 10% FBS 
supplement.  The cells were seeded at 10,000 cells/well/200 µL in a 96 well tissue culture 
plate and allowed to grow for 24 hours under incubation at 37°C in 5% CO2.  The cells 
were then treated with different concentrations of nanogel-caspase conjugates and were 
incubated for another 24 hours.  Cell viability was measured using Alamar Blue assay 
with each data point measured in triplicate.  Fluorescence measurements were made 
using the plate SpectraMax M5 by setting the excitation wavelength at 560 nm and 
monitoring emission at 590 nm on a black 96 well flat bottom plate.   
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.13 Apoptosis experiment performed with nanogel-caspaseRRR on day two. 
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CHAPTER 3 
TRI-FUNCTIONALIZATION OF AMINE-BASED SCAFFOLDS UTILIZING AN 
EPISULFIDE MOIETY  
 
3.1 Introduction 
     The development of new strategies for preparing materials endowed with multiple 
functions has attracted attention in the field of nanotechnology with potential 
implications in sensing,1–4 theranostics5–10 and biomedical applications11–13. Such 
materials combining several functionalities can significantly enhance specificity and 
capabilities within a single nanoscale construct. Significant efforts have been devoted to 
the development of nanomaterials incorporating polyethylene glycol which adds 
biological stealthiness thus improving stability in blood circulation,14,15 enhancing tissue 
targeting, and  reducing toxicity.16–19 Simultaneously, the same nanoscaffold can be 
modified with cell-penetrating moieties20–23 and imaging agents24,25 to monitor the drug 
transport process. Although previous efforts have resulted in functionalized scaffolds 
with promising properties the vast majority of examples in literature describe a bi-
functionalization approach.   
     Scaffolds possessing both therapeutic and diagnostic capabilities have emerged as 
potential candidates in theranostics.7–10 Typically, these materials lack targeting 
capabilities, so introducing a targeting moiety as an additional functionality could 
significantly improve the efficacy of these systems. However, incorporating three 
functional molecules in one nanoplatform simultaneously is a rather challenging task. For 
instance, typical strategies involve non-covalent interactions such as electrostatics26,27 and 
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hydrophobic adsorptions28,29 however these systems do not enable absolute control over 
the location or composition of the functional group within the scaffold. On the other 
hand, covalent strategies offer better control over conjugation and quantification of 
different functionalities. However, covalent attachment of guest molecules is more 
specific towards particular reactive functional groups. Few reports describe the 
preparation of tri-functional materials involving the covalent conjugation of imaging 
agents, membrane translocation peptides, cell-targeting moieties and histidine-rich 
peptides for lysosomal escape.20,23,24,30 These reports however, are considered tri-
functional due to their therapeutic, imaging and cellular uptake capabilities in a single 
particle. In most cases, these multi-functionalization capabilities rely on the topology or 
architecture of the scaffold it self. For instance, mesoporous silica nanoparticles provide 
three distinct domains (silica framework, pores/channels, surface), which can be 
independently functionalized.23 However, there is difficulty in selectively combining 
multiple functions within a single domain such as its surface. An advantage of multi-
functionalizing the scaffold’s surface is that the core remains available for further 
encapsulation or modification. Unfortunately, one of the present limitations with surface 
functionalization is that the functional density is limited due to the lack of chemical 
selectivity and functional groups.  In this chapter, we describe a methodology for the 
preparation of tri-functionalized materials with higher functional density, which hold 
potential in multi-functionalization of scaffold surfaces.  
3.2 Results and Discussion 
     Our approach is by using primary amines as the scaffold’s initial surface functional 
group.  Using amines is advantageous due to their high reactivity with a wide range of 
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functional groups such as epoxides,31,32 activated esters,33,34 aldehydes,35 carboxylic 
acids36,37, among others.  The proposed methodology involves the use of an episulfide-
containing molecule as the initial functionality introduced due to its reactivity with 
primary amines. The opening of the heterocyclic ring will lead to the development of a 
new entity with nucleophilic character after the generation of a secondary amine and a 
thiol group. A second functionality can be introduced utilizing a disulfide-containing 
molecule to selectively couple with the free thiol generated. Due to the difference in 
reactivity of the amine and free thiol, the first two functionalizations with the episulfide 
opening and di-sulfide conjugation can be in theory be done in one step. Lastly, a reactive 
compound such as an isothiocyanate molecule can then be introduced to react with the 
remaining secondary amine.  In this design tetraethylene glycol monomethyl ether 
episulfide was used as the first functionality to react with amine groups present on the 
scaffold (Figure 3.1). Incorporating ethylene glycol moiety will introduce hydrophilicity 
and biocompatibility to the system.  This reaction will generate a secondary amine and a 
thiol group to be used as handles for a second and third functionality.  
 
     5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) also known as the Ellman’s reagent will 
be used as the second functionality. The free thiol generated after reacting the amine and 
Figure 3.1 Representation and chemical structures of the functionalities for the tri-
functionalization process of amine-containing scaffolds.   
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episulfide can selectively react with the Ellman’s reagent cleaving the disulfide bond and 
releasing 2-nitro-5-thiobenzoic acid (TNB) (Scheme 3.1). Release of TNB can be 
quantified via absorption of visible light at 412 nm (Scheme 3.1) allowing for 
quantification of di-sulfide conjugation onto the scaffold.38 The remaining secondary 
amine generated will be then reacted with an isothiocyanate functional group.   In this 
case fluorescein isothiocyanate was employed as the third functionality.  
     Among the different candidate scaffolds for surface functionalization, amphiphilic 
polymeric nanoparticles are ideal due to their ability to encapsulate and release guest 
molecules within their interior.39–41 Additionally, nanoparticles have high surface area 
that could be utilized for multi-functionalization. However, their surface functionalization 
capabilities are limited due to the lack of selective reactivity of functional groups. In 
order to determine if this approach could be applicable to scaffolds with different 
morphology and functional group density we were also interested in applying this 
methodology to dendrimers.  These scaffolds are considered exceptional nanomaterials 
due to their unique properties including, hyper-branched globular shape, narrow 
polydispersity index and control over molecular structure.  Since dendrimers possess high 
density of functional groups on their molecular surface, we were interested in examining 
this approach in scaffolds where the conjugation could be challenging due to sterics.  
Scheme 3.1 Reaction of the 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) or Ellman’s 
reagent with a thiol (R-SH). 
	   63	  
3.2.1 Scaffold Di-functionalization and Characterization 
     Polymeric nanoparticles previously reported in our group42 and PPI G4  dendrimers 
were dispersed in sodium phosphate buffer pH 8. The one pot dual functionalization 
reaction was carried after co-dispersing the nanoparticle (Scheme 3.2.A) and dendrimer 
(Scheme 3.2.B) with the Ellman’s reagent. Triethylene glycol monomethyl ether 
episulfide was then added slowly to the solution and the reaction mixture was allowed to 
react at 50 oC for 22 hours.  
	  
 
Scheme 3.2 Di-functionalization reaction of the (A) nanoparticle (B) PPI G4 
dendrimer. 
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The progress of the di-functionalization reaction was monitored by the absorption of the 
TNB released over time (Figure 3.2). After 3 to 4 hours the generation of TNB reached 
saturation presumably due to the consumption of the episulfide-containing molecule. The 
extent of functionalization was then quantified assuming that each Ellman’s reagent 
attached is equivalent to the moles of episulfide conjugated onto the scaffold. Based on 
the extinction coefficient of TNB, the amount of amine moieties from the nanoparticle 
(Figure 3.2.A) that reacted with the episulfide-containing molecule and Ellman’s reagent 
is 79%. The nanoparticles were prepared at pH 2 to allow the protonation of the amine 
moieties.42 At this pH the polymer self-assembles in to an amphiphilic aggregate where 
the amines groups are exposed towards the outside of the assembly.  The core is then 
crosslinked through photochemical reaction of the coumarin moieties.  We believe that 
this 79% conjugation corresponds to the percentages of amines accessible for conjugation 
since some of these moieties might be buried in the interior of the nanoparticle. In the 
case of the dendrimer (Figure 3.2.B) and based on the extinction coefficient of TNB, 
Figure 3.2 Absorption spectra of TNB to monitor the progress of di-functionalization 
reaction of (A) nanoparticle (B) dendrimer. The concentration used for the absorption 
spectra was 0.1 mg/mL for the nanoparticle and 0.005 mg/mL for the dendrimer. 
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100% of amines reacted and were conjugated to the tetraethylene glycol monomethyl 
ether episulfide and Ellman’s reagent.  	  	  	  	  	  After purification, the surface modification was evaluated by FTIR. The FTIR 
spectrum of modified nanoparticles showed two distinct peaks around 1518 cm-1, 1338 
cm-1 (Figure 3.3.A) and 1518 cm-1 and 1359 cm-1 (Figure 3.3.B) corresponding to the 
stretching vibrations of N-O for both the nanoparticle and the dendrimer from the 
Ellman’s reagent. To further confirm the di-functionalization reaction and considering the 
deprotonated form of the carboxylic acid from the Ellman’s reagent at pH 7.4, we 
evaluated the change in the surface charge by zeta potential measurements (Figure 3.3).  
As expected, the surface charge of the nanoparticles before functionalization was found 
to be 3.27 mV.  In the case for the di-functionalized nanoparticle, the value shifted 
towards -49.2 mV suggesting the conjugation of the Ellman’s reagent onto the surface of 
the nanoparticles (Figure 3.3.C). Similarly, the surface charge reflects a value of 7.5 mV 
for non-modified dendrimer whereas the value observed for di-functionalized dendrimer 
shifted towards negative values, -18.1 mV (Figure 3.3D). 
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3.2.2 Scaffold Tri-functionalization and Characterization  
     Secondary amines are known to be reactive with isothiocyanate groups.43,44 To 
evaluate if this amine could be used as a handle to attach a third functionality we utilized 
fluorescein isothiocyanate (FITC). An excess amount of FITC was added and the reaction 
mixture and allowed to react overnight at room temperature (Scheme 3.3). After 
dialyzing out excess FITC conjugation thiourea stretches were confirmed via FTIR for 
tri-functionalized scaffolds (Figure 3.4). The C=S vibrations were observed in the case of 
the nanoparticle (Figure 3.4.A) around 1165 cm-1 and 1212 cm-1 for the dendrimer 
(Figure 3.4.B).  
 
Figure 3.3 FTIR spectra of di-functionalized (A) nanoparticle and (B) PPI G4 dendrimer.  
Zeta potential measurements for (C) nanoparticle and (D) PPI G4 dendrimer. 
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To further confirm the conjugation of FITC we took the absorption spectra of the tri-
functionalized nanoparticle (Figure 3.5.A) and dendrimer (Figure 3.5.B). As predicted, a 
peak around 495 nm was observed corresponding to the maximum absorption of FITC.  
In addition, a peak around 350 nm is observed corresponding to the half of the Ellman’s 
reagent molecule attached to the scaffold.  Based on this graph we can also determine that 
for the case of the nanoparticle the ratio between conjugated half Ellman’s reagent and 
FITC is about 1: 0.8.  Similarly for PPI G4 dendrimer, the ratio for conjugated half 
Ellman’s reagent and FITC is 0.7 : 1.  
 
 
 
 
Figure 3.5. Absorption spectra of tri-functionalized (A) nanoparticle (B) PPI G4 
dendrimer. The concentration was 1 mg/mL for nanoparticle and 0.05 mg/mL for 
dendrimer. 
Figure 3.4 FTIR spectra of tri-functionalized (A) nanoparticle (B) PPI G4 dendrimer.  
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3.3 Summary 
     In this chapter we report a straightforward methodology for the preparation of tri-
functionalized amine materials with high functional density is presented. Our approach is 
based in the use of an episulfide-containing molecule being the first functionality 
introduced due to its reactivity with primary amines causing the generation of a 
secondary amine and free thiol group. The second molecule introduced will have a 
disulfide to selectively couple with the free thiol generated. Lastly a reactive compound 
such as isothiocyanate molecule will be introduced to react with the remaining secondary 
amine. This approach can be applied to construct multifunctional nanoscaffolds with high 
surface functionality for potential in biomedical applications.  
3.4 Experimental Details 
     5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB), tetraethylene glycol monomethyl ether, 
epichlorohydrin, PPI G4 dendrimer, epichlorohydrin, sodium hydride, sodium 
thiocyanate, and fluorescein isothiocyanate were obtained from commercial sources and 
used without further purification. Polymeric nanogel was prepared using the previously 
reported procedure. (ACS Macro Lett. 2013, 2, 948-951). 1H-NMR spectra were recorded 
on a 400 MHz Bruker NMR spectrometer using the residual proton resonance of the 
solvent as the internal standard.  Chemical shifts are reported in parts per million (ppm). 
Dynamic ligth scattering (DLS) and zeta potential measurements were performed using a 
Malvern Instrument Nanozetasizer.  UV-Visible absorption spectra were recorded on a 
Varian (Model EL 01125047) spectrophotometer.  The fluorescence spectra were 
obtained from a JASCO FP-6500 spectrofluorimeter. FTIR spectra were recorded on a 
Perkin Elmer spectrometer.  
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3.4.1 Synthetic Protocols and Characterization for Compounds 
Synthesis of the Triethylene Glycol Monomethyl Ether Episulfide: 
 
 
Synthesis of (±)-(2,5,8,11-tetraoxadodecyl)oxirane:  
     To a solution of triethylene glycol monomethyl ether (20 mL, 125 mmol) in THF (125 
mL) was added NaH (9g, 60% in mineral oil). Mixture stirred for 2 h. at rt before slowly 
adding epichlorohydrin (39 mL, 500 mmol). The reaction mixture was stirred at rt for 13 
h. before filtering through celite and concentrated in vacuo to give a yellow oil. (J. Am. 
Chem. Soc. 2011, 133, 14260-14263) The crude product was purified by silica gel flash 
chromatography eluting up to 10 % MeOH/DCM yielding a clear oil (16.2 g, 74 mmol, 
59%). 1H NMR (400 MHz, CDCl3) δ 3.76 (m, 1H), 3.64 (m, 10H), 3.52 (m, 2H), 3.38 (m, 
1H), 3.34 (s, 3H), 3.13 (m, 1H), 2.76 (m, 1H), 2.58 (m, 1H) 13C NMR (100 MHz, CDCl3) 
δ 71.98, 71.92, 70.7, 70.6 (overlapping peaks), 70.5, 59.0, 50.8, 44.3.   
 
Scheme 3.3 Synthesis of the triethylene glycol monomethyl ether episulfide. 
O OH3
O Cl
O O3
O
NaSCN (aq)
NaH, DMF 55%
38%
S
OO 3
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Figure 3.6 1H NMR (A) and 13C NMR (B) of the (±)-(2,5,8,11-
tetraoxadodecyl)oxirane or the triethylene glycol mono methyl ether epoxide. 
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Synthesis of (±)-(2,5,8,11-tetraoxadodecyl)episulfide:  
     To (±)-(2,5,8,11-tetraoxadodecyl)oxirane (2.0g, 9.1 mmol) was added aqueous 
NaSCN (20 mL, 1M). The reaction was stirred at room temperature for 24 hours before 
diluting in water and extensively washing with ether. Organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo. (Org. Biomol. Chem. 2009, 7, 1397–1403). 
The crude product was purified via silica gel flash chromatography eluting up to 10% 
MeOH/ DCM to afford a clear oil (1.2 g, 55 %) 1H NMR (400 MHz, CDCl3) δ 3.62 (m, 
11H), 3.54 (m, 2H), 3.48 (dd, J = 10.8, 6.84 Hz, 1H), 3.37 (s, 3H), 3.08 (m, 1H), 2.51 (dt, 
J = 6.20, 1.0 Hz, 1H), 2.21 (dd, J = 5.38, 1.26 Hz, 1H) 13C NMR (100 MHz, CDCl3) δ 
75.9, 72.0, 70.6 (overlapping peaks), 70.5, 70.4, 59.1, 32.1, 23.9; HRMS (ESI) calcd. for 
C10H20O4S (M+Na) 259.0957, found 259.0983.  
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Figure 3.7 1H NMR (A) and 13C NMR (B) of the (±)-(2,5,8,11-
tetraoxadodecyl)episulfide or the triethylene glycol mono methyl ether episulfide. 
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Synthesis of the N-2-[(tert-butoxycarbonyl)amino] ethyl methacrylamide (Boc-
AEMA)-co-4-methylcoumarin-7-oxypropyl methacrylamide (CPMA) random 
copolymer:  
     The boc-protected random co polymer was synthesized according to the previously 
reported procedure via RAFT polymerization (ACS Macro Lett. 2013, 2, 948–951). 1H 
NMR (400 MHz, CDCl3) δ 7.3-7.4, 6.5-6.9, 5.9-6.1, 3.9-4.1, 3.0-3.4, 2.1-2.4, 1.9-2.0, 
O
NH
O
O
O
O
NH
HN
O
O
NH
O
NH
HN
OO
O
O
0.7n 0.3n
O
O
+
S
S CN
OH
O
AIBN, DMF
Scheme 3.4 Synthesis of the Boc-AEMA-co-CPMA random copolymer. 
Figure 3.8 1H NMR spectrum of the Boc-AEMA-co-CPMA. Methyl proton signals of 
the Boc group at 1.3-1.4 ppm. 
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1.7-1.8, 1.3-1.4, 0.9-1.2 
Synthesis of the de-protected AEMA-co-CPMA random co-polymer:  
      
 
 
 
 
 
The deprotection reaction and purification was carried out as previously reported. (ACS 
Macro Lett. 2013, 2, 948–951). 1H NMR (400 MHz, DMSO-d6) δ 7.8-8.0, 7.3-7.7, 6.7-
6.9, 6.0-6.2, 3.9-4.1, 3.0-3.2, 2.80-2.84, 2.2-2.4, 1.6-1.9, 0.7-1.0 
NH
O
NH
H3N
OO
O
O
0.7n 0.3n
NH
O
NH
HN
OO
O
O
0.7n 0.3n
O
O
TFA, DCM
Scheme 3.5 Boc-deprotection of the AEMA-co-
CPMA random copolymer 
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3.4.2 Control Experiment: Ellman’s reagent exposed to pH 8.   
     Ellman’s reagent was exposed to sodium phosphate buffer pH 8 and the absorption 
spectra were recorded over a period of 22 hours. The reagent is stable over this period of 
time.  Ellman’s reagent was broken releasing the TNB after exposing it to pH 10. 
Figure 3.9 1H NMR spectrum of the deprotected AEMA-co-CPMA. 
Figure 3.10 Absorption spectra of Ellman's reagent exposed to pH 8 for up to 20 
hours indicating the stability of this reagent at this pH. 
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3.4.3 Control Experiment: Ellman’s reagent exposed to 50 oC.  
     Ellman’s reagent was dissolved in sodium phosphate pH 8 buffer and and placed in a 
snad bath at 50 oC for 18 hours.  Ellman’s reagent is stable under these conditions. 
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CHAPTER 4 
 
 EFFECT OF PARTITION COEFFICIENT IN DRUG LOADING AND 
ENCAPSULATION EFFICIENCY IN POLYMERIC NANOGELS 
 
4.1 Introduction 
     Polymeric nanoparticles have attracted attention as delivery systems due to their 
ability to sequester, transport and selectively release hydrophobic guest molecules under 
certain stimuli conditions.1–5 A critical factor for an efficient delivery vehicle is the 
capacity to stably encapsulate guest molecules to prevent drug leakage during circulation 
thus reducing unwanted toxicity.  Therefore, an understanding of the dynamics of guest 
exchange with the bulk media is imperative. Our group recently reported the 
development of a fluorescence resonance energy transfer (FRET) based assay to evaluate 
the encapsulation stability of polymeric nanogels in aqueous media.6 In this method a 
lipophilic FRET pair 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate 
(DiI, acceptor) and 3,3’-dioctadecyloxacarbocyanine perchlorate (DiO, donor) were 
independently encapsulated in polymeric nanogels.  When these solutions are mixed two 
limiting scenarios are possible (Figure 4.1).  
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If the dyes are stably encapsulated within the polymeric nanogels, the guest molecules 
will not exchange with the bulk solvent and will remain in their original container. In this 
case there will be no FRET observed because the distance between these two pairs will 
exceed their Förster radius. On the other hand, if the lipophilic molecules exchange 
between the container interior and the bulk solvent, the dyes will equilibrate between the 
two containers, occupying the same nanogel leading to increased FRET. Thus, 
monitoring the evolution of FRET over time provides us with insight into the exchange 
dynamics with the bulk environment and the stability of guest encapsulation. Utilizing 
this methodology, our group has also investigated the encapsulation stability of guest 
molecules in an environment that mimics cells by utilizing dioleoyl phosphatidylcholine 
(DOPC) bilayer vesicles.7 We have also studied the effect of scaffold hydrophobicity in 
drug loading and encapsulation with this methodology.8 However, DiO and DiI are 
highly lipophilic molecules with a partition coefficient (log P) value greater than 10.9 
Figure 4.1 Potential FRET outcomes upon mixing nanogels independently encapsulating 
DiI and DiO.  
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(Molinspiration Property Calculation Service (www.molinspiration.com) On the other 
hand, the log P values of drug molecules available to treat diseases rely on values lower 
than 10 (Table 4.1). 
 
 
Drug Log P Uses 
Docetaxel 4.2610 Anticancer 
Doxorubicin 1.311 Anticancer 
Paclitaxel 3.9612 Anticancer 
Dexamethasone 1.7913 Anti-inflammatory and immunosuppressant 
Phenytoin 2.1413 Convulsion and seizures 
Diazepam 2.9813 Anxiety and panic attacks 
Cisplatin 2.3514 Anticancer 
Mannitol -3.1015 Osmotherapy, head trauma cranial pressure 
 
Therefore, if we were to use these nanogels as potential delivery vehicles it is crucial to 
understand the effect of the dye’s hydrophobicity on the dynamics of guest exchange.  In 
this chapter, we study the effect of the log P value of guest molecules on the 
encapsulation efficiency and ultimately the loading capacity. 
 
 
Table 4.1 Partition coefficient (log P) value for some drug molecules. 
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4.2 Molecular Design and Results 
     Our approach is to utilize our polymeric nanogels and encapsulate FRET partner dyes 
with different lipophilicities. Also, we were interested in understanding the role of drug 
loading and crosslinking density in encapsulation stability. Our goal is to encapsulate 0.5, 
2 and 10 weight percent (wt%) of each dye. The crosslinking density will be varied 
having non-crosslinked polymer aggregates and 100% crosslinked nanogels as controls. 
We chose our PEG:PDS polymeric nanogels as the target scaffold with a ratio of 26% 
PEG and 74% as discerned by NMR (polymer synthesis and NMR by Mallory Gordon). 
Nanogels were synthesized by exposing the polymer to an aqueous solution and the self-
crosslinking process was enabled by intra- and inter-chain disulfide cross-linking of the 
PDS groups in the presence of the reducing agent dithiothreitol (DTT) (Figure 4.2A).  
FRET pairs were chosen according to their predicted Log P value obtained from the 
Molinspiration Interactive Log P calculator (Figure 4.2B and 4.3). This property 
calculator service was validated by comparing predicted values of different molecules 
with their corresponding experimental Log P found in literature (Table 4.2). In this 
project, we will use naphthalene/N-dansyl ethylamine, pyrene/perylene and DiO/DiI for a 
Log P value of ~3, 5 and 10, respectively. 
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Figure 4.3 Chemical structures of the FRET pairs from each Log P value studied. Log P 
values were predicted using the Molinspiration Interactive Log P calculator. 
Figure 4.2  (A) Synthesis of the nanogels intra- and inter-chain disulfide cross-linking of 
the PDS groups in the presence of the reducing agent DTT (B) Molinspiration Interactive 
Log P calculator 
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Compound Literature log P Value Predicted log P Value 
Molinspiration Software 
Aspirin 1.1416 1.87 
Salicylamide 1.2817 1.20 
Naphthalene 3.3418 3.10 
Anthracene 4.5018 4.30 
Benzene 2.1319 1.90 
 
 
 
 
 
4.2.1 Pyrene and Perylene Spectral Overlap and Nanogel Sizes  
We started our experiments utilizing pyrene and perylene since these dyes were readily 
available in our lab.  In order for FRET to occur the absorption spectrum of the acceptor, 
in this case perylene, must overlap with the fluorescence emission spectrum of pyrene, 
the donor.  To evaluate if these dyes meet this requirement, we prepared solutions with 
Table 4.2 Validation of the Molinspiration Software with Literature Values.  
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0.005 mg/mL of pyrene and perylene in dimethyl sulfoxide and the emission and 
absorption spectra were recorded (Figure 4.4B). Then, we proceeded with the synthesis 
of the polymeric nanogels encapsulating 0.5 wt% pyrene and perylene by in situ loading.  
The size of the resulting nanogels encapsulating pyrene was evaluated by dynamic light 
scattering (DLS) and found to be 21, 18 and 15 nm for 5, 12 and 100 % crosslinked 
nanogels, respectively (Figure 4.5A).  The size slightly decreased as the crosslinking 
density increased. On the other hand, the size for nanogels encapsulating perylene 
increased from 13, 15 and 28 nm as the crosslinking density increased (Figure 4.5B).  
These differences could be attributed to the packing of each dye within the nanogels. 
Figure 4.4 (A) Absorption spectra of pyrene and perylene (B) Overlap spectra of FRET 
pairs pyrene and perylene. Samples prepared at a concentration of 0.005 mg/mL in 
dimethyl sulfoxide. 
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4.2.2 Encapsulation Efficiency Evaluation 
     In order to evaluate their encapsulation efficiency, we calculated the dye loading 
amounts of dye for each sample based on the recorded absorbance values of the purified 
nanogels. Since the pyrene monomer fluorescence shows strong solvent dependence we 
evaluated the environment polarity of encapsulated pyrene. For this, the emission 
spectrum of 5% crosslinked nanogels encapsulating pyrene was recorded and normalized 
with reference to the I1 peak (Figure 4.6A).  Since the I3 peak shows maximum variations 
in intensity relative to I1 peak, the intensity of I3/I1 will be used to determine the 
environmental effects on pyrene fluorescence by comparing with relative peak intensities 
for the five principal vibronic bands in various solvents.20  Based on this analysis it was 
determined that the relative intensity of pyrene monomer fluorescence matched that 
observed in chloroform (CHCl3).  Therefore the absorption spectra of different 
concentrations of pyrene and perylene in CHCl3 were recorded (Figure 4.6B).   
Figure 4.5 Dynamic light scattering of 0.1 mg/mL aqueous solution of nanogels 
encapsulating (A) pyrene and (B) perylene. 
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A calibration curve was prepared for pyrene (Figure 4.7A) and perylene (Figure 4.7B) 
and the extinction coefficients were found to be 28047 M-1cm-1 and 27120 M-1cm-1, 
respectively. After removing the excess dye and by-products of the crosslinking reaction 
by dialysis, guest encapsulation in these nanogels was measured by UV-visible 
spectroscopy.  The absorption spectra of nanogels loading pyrene (Figure 4.7C) and 
perylene (Figure 4.7D) was recorded in order to calculate the extent of guest loading. As 
observed in Table 3A, the encapsulation for pyrene was 100% efficient independently of 
the crosslinking density of the nanogels whereas for perylene this was not the case.  The 
highest loading was achieved by polymer aggregates with 34% efficiency whereas the 
lowest encapsulation (11%) was observed for nanogels with 100% crosslink density.  
This difference can be attributed possibly to the influence of perylene π- π interactions 
which could affect the self-assembly of the polymer and thus loading. The amount of 
Figure 4.6  (A) Normalized emission spectrum of 5% crosslinked nanogels 
encapsulating 0.5 wt% pyrene. Concentration of the sample was 0.1 mg/mL (B) 
Absorption spectra of different concentrations of pyrene and perylene in chloroform.  
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perylene fed into the polymer solution was increased up to 0.15 mg but after purification 
the encapsulation efficiency didn’t increase significantly (Table 4.3B).  
 
After evaluating the loading efficiency of these dyes, we were then interested in 
investigating the encapsulation capabilities of nanogels with this pair of dyes possessing a 
log P value between 5.2 – 5.8. We utilized a FRET-based assay for which nanogel 
samples encapsulating pyrene were mixed with those containing encapsulated perylene 
with both nanogels having equal concentrations of 0.1 mg/mL in the resulting mixture. 
The time-dependent FRET evolution along with the absorption spectra of the mixed 
Figure 4.7 Calibration curve of (A) pyrene and (B) perylene in CHCl3 prepared to 
determine the extinction coefficient for each dyes. Absorption spectra recorded of 
nanogels (0.1 mg/mL) with different crosslinking densities loading 0.5 wt% (C) 
pyrene and (D) perylene. 
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nanogel solutions is plotted in Figure 4.8. As observed in this figure, nanogels 0% and 
100% crosslinked (Figure 4.8A and D) exhibited faster FRET rates over a period of 6 
hours with a rapid burst of FRET within the first 90 minutes.  On the other hand 5% 
crosslinked nanogels (Figure 4.8B) displayed the steadiest FRET evolution suggesting 
that this crosslinking density provides the most stable encapsulation.  Nanogels 15% 
crosslinked (Figure 4.8C) showed the most fluctuations in FRET especially during the 
first 2 hours.  However, it is important to note the difference in the loading amount of 
perylene. This variable could potentially influence the dye exchanges. 
 
Table 4.3 Summary of the percentage of crosslinking density and encapsulation 
efficiencies. 
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Figure 4.8 FRET evolution spectra of nanogels (A) 0% (B) 5% (C) 15% (D) 100% 
crosslinked. Absorption spectra of nanogels (E) 0% (F) 5% (G) 15% (H) 100% 
crosslinked. These measurements were taken at a concentration of 0.1 mg/mL. 
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4.3 Summary 
     In this chapter we utilized our redox-sensitive polymeric nanogels composed of 
oligo(ethylene glycol) methacrylate and pyridyldisulfide methacrylate to investigate the 
effect that the guest molecule’s lipophilicity has with respect to the encapsulation 
efficiency. We utilized a variety of guest molecules with different partition coefficient 
values (log P). We were able to prepare nanogels encapsulating pyrene and peylene 
(predicted log P 5.2 – 5.8) with different crosslinking densities.  At this log P range, the 
encapsulation of pyrene was significantly more efficient than was observed for perylene.  
Preliminary FRET based experiments show that slightly (5%) crosslinked nanogels 
provide the more stable encapsulation of guest molecules possessing this log P value. 
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CHAPTER 5 
 
 
 SUMMARY AND FUTURE DIRECTIONS 
 
5.1 Summary 
     Nanoparticles have recently emerged as potential candidates for use as carriers in 
delivery applications, theranostics, and sensing among others.  While nanoparticles can 
be prepared from metals and inorganic materials, polymeric nanoparticles allow non-
covalent guest encapsulation and surface functionalization. Additionally, their structure 
can be modified to achieve biocompatible materials. In this dissertation, we focus our 
work on the use of amphiphilic random copolymers and their tendency to self-assembly 
in aqueous solution.  These micellar aggregates are then converted into nanoparticles in 
one step without the need for further modifications.  
     In Chapter 1, we discussed the characteristics or requirements that a nanoparticle must 
possess to be utilized as a carrier for biomolecules and drugs. In Chapter 2, we studied 
the use of PEG-PDS polymeric nanogels for “locking-in” the structure of a protein by 
polymer conjugation, simultaneously protecting its delicate folded state and silencing its 
enzymatic activity. This method also allows recovery of activity only upon cytosolic 
uptake, which triggers the release from the polymer. The release of the apoptotic protein 
was assessed through enzymatic activity and cell viability assays. In Chapter 3, we 
describe a straightforward methodology for the preparation of tri-functionalized amine 
materials with high functional density. We targeted primary amines as the scaffold’s 
surface functional group to couple with three different molecules; an episulfide-
containing molecule, Ellman’s reagent and fluorescein isothiocyanate. In Chapter 4 we 
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introduced a new project that was started in July of 2014 with the main objective of 
investigating the effect that the guest molecule’s lipophilicity has with respect to the 
encapsulation efficiency of nanogels. Although pyrene and perylene were encapsulated 
into the PEG-PDS polymeric, we observed poor encapsulation efficiency for perylene 
compared to pyrene.  
 
5.2 Future Directions 
     In Chapter 2 we were able to demonstrate the successful conjugation of caspase-3 on 
either the interior or the surface of nanogels by a thiol-disulfide exchange reaction 
between unreacted polymer PDS groups and surface exposed cysteine residues in the 
protein.  However, it would be useful to determine the amount of protein per nanogel 
particle. Although nanogels lacking cell-penetrating peptides showed less cell 
internalization than the RRR nanogels, these nanogels were more efficient at inducing 
cell death. Therefore, it would be useful to identify the cell internalization mechanism in 
order to determine if these nanogels are in fact becoming entrapped in endosomes. We 
utilized RRR peptide as a proof-of-concept but it would be beneficial to utilize a more 
biologically relevant and/or neutral ligand to avoid charge interference with 
internalization.  
     In Chapter 3 we describe a methodology to tri-functionalize amine-containing 
polymeric materials.  Our approach is based on the use of an episulfide-containing 
molecule, as the first functionality introduced due to its reactivity with primary amines 
causing the generation of a secondary amine and thiol group. The second molecule 
introduced will have a disulfide to selectively couple with the free thiol generated. Lastly 
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a reactive compound such as isothiocyanate molecule is introduced to react with the 
remaining secondary amine. Pre-eliminary findings in our group suggest that a small 
percentage of amines could react with disulfides. For this methodology to be effective 
and in high yields we need to make sure that there is no side-reaction occurring between 
the amine-containing scaffold and the Ellman’s reagent. Therefore, we should monitor 
the absorption spectra over time of Ellman’s reagent in the presence of the nanoparticle 
and/or PPI dendrimer at pH 8. This experiment should be carried out at the same 
concentration we utilized to monitor the di-functionalization reaction (~0.1 mg/mL). In 
addition, we should apply this methodology to other scaffolds including polymer and 
metal-nanoparticles. As a proof-of-concept we utilized tri-ethylene glycol, Ellman’s 
reagent and fluorescein isothiocyanate but this work could have potential implication in 
theranostics applications if we utilize for example an episulfide-containing drug 
molecule, a targeting antibody /ligand and a Near Infrared Light (NIR) dye molecule. 
     In Chapter 4 we were able to encapsulate pyrene and perylene into PEG-PDS 
polymeric nanogels.  However the encapsulation efficiency was poor for perylene 
possibly due to stronger π-π interactions. Therefore, for this log P range (~5) we should 
utilize Cy3 and Cy5 since the log P value of these dyes falls within this range and will 
eliminate any complications due to π-π stacking.  
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